Index

abdominal pregnancy,	severe acute maternal morbidity in	analgesia,
case reports 583	501	and PPH risk 142
diagnosis 584	age,	for balloon insertion 391
hemorrhage from 583-6	mortality and 170	anaphylaxis and blood transfusion 39
incidence 584	placenta accreta incidence and 247	anastomoses,
timing of intervention 584	placenta previa risk 231	between uterine and vaginal arteries
abdominal wall, bleeding from during	PPH incidence and 152, 155	20, 21
cesarean section 448	PPH risk 139	between uterine arteries with arteries
ABO compatibility 31	airway management 520	to lower ureters 404
abortion 276, 277	alcohol effect on vascular system 403	major pelvic 442
morbidity reduction after 286	algorithms,	of internal iliac artery 442
using misoprostol 285	blood transfusion refusal care	subplacental uterine network 490
accurate rate determination 152–8	pathway 595	tying of uterine and ovarian
acid hematin method 84	instrumental delivery and PPH 5	anastomoses 452
acidosis as part of 'lethal triad' 24	management of major PPH 196	uterine anastomotic system 267
acquired disorders of hemostasis 199–204	management of placenta accreta 243	anatomy,
acquired hemophilia 206	management of PPH 349	of internal iliac artery 441
acquired vascular malformations 218	PPH after elective cesarean section 7	for internal iliac artery ligation 455 of uterine arteries 177–83
active management of third stage of labor	PPH after emergency cesarean	pelvic vessels 445
(AMTSL) 101–106, 113–124	section in first stage of labor 8	1
cf expectant 105, 113, 126 components of 66	PPH in elective cesarean for	surgical for placenta accreta management 264
current guidance for clinicians 124	adherent placenta 10	vascular supply of pelvis 332,
EUPHRATES consensus on 111	PPH in emergency cesarean for	399–400
FIGO guidelines on 608	adherent placenta 11	anemia,
historical 60	PPH in failed sequential instrumental	antenatal correction 165, 194
in Benin 123	delivery/emergency cesarean	delayed clamping of cord and
in Mali 123	9	reduction 118
misoprostol cf oxytocin 284	PPH management in UK 167	management in women refusing
PPH incidence and 113, 157	PPH scenario in vaginal delivery 4	blood transfusion 598
recommendations for 361	proposed management scheme	management postpartum in
suggested steps in 117–19	within hospitals 343	Jehovah's Witnesses 591
techniques for and comparison of	recommended protocol for placenta	angiogram,
studies 134	accreta/increta/percreta	arterial anastomotic system between
uterotonic agents 101–5, 114	410	vaginal and uterine arterial
without controlled cord traction	tamponade method 390	systems 20
116	use of internal uterine balloon 385	false aneurysm 471
acute fatty liver of pregnancy 204	allergic reaction	proof of pseudoaneurysm 222, 223
acute hemolytic transfusion reaction 37	to blood transfusion 39	pseudoaneurysm of uterine artery 13
acute normovolemic hemodilution 591, 592	to iodine 409	animal studies of pneumatic anti-shock
acute uterine inversion 185–8	alloantibodies 31	garments 333
ADAMTS 13 204	alloimmunization 27, 37, 356 amniotic fluid,	antenatal PPH prevention 549 antepartum hemorrhage and PPH risk 140
adherent placenta, see placenta accreta,	cell salvage methods contraindicated	anti-shock garments,
placenta increta, placenta percreta	by presence of 578	G-suit 319
Afghanistan, misoprostol use in 557	in vitro studies of clearance 579	history of 331
afibrinogenemia 212, 213	leukocyte depletion filters 580	medical anti-shock trousers 318
Africa,	amniotic fluid embolism 491	non-pneumatic anti-shock garment
B-Lynch compression suture use in	as a cause of consumptive	315, 318–328, 331–339,
437	coagulopathy 205	454, 558
maternal morbidity 137	cell salvage methods and 578	pneumatic anti-shock garment 318,
maternal mortality 136	in Japan 172	319

use for abdominal pregnancy 585	misoprostol use in 286	PPH and 55
antibiotic use in secondary PPH 469	Belfort-Dildy Obstetrical Tamponade	Brandt-Andrews technique for AMTSL
anticoagulant therapy,	System 460	134
during pregnancy and peripartum	Belgium, accurate PPH rate	BRASSS-V drape TM 81, 84–6, 134, 557
206–8	determination in 154	breast milk 362
epidural anesthesia and 207	Benin, active management of third stage	breathing management 520
antifibrinolytic therapy 36	of labor in 123	broad ligament arteries, prepregnancy
antiphospholipid syndrome 201	Bernard–Soulier syndrome 208	hemodynamics 179
aortic compression 6	bimanual compression of uterus 434	BT-Cath balloon 369
FIGO guidelines on 613	FIGO guidelines on 613	
intraoperative 10	biochemical markers for placenta accreta	
arterial blood pressure measurement 76	248	calibrated drapes 84-6
arterial embolization 5	biologically active topical hemostatic	Canada,
for cervical and vaginal vault tears	agents 481–5	accurate PPH rate determination
195	bipartite placenta 236	153
for supralevator hematoma 197	bipedal locomotion and PPH 59	B-Lynch suture compression suture
in secondary PPH 470	bladder,	use in 438
selective during operative delivery	adherent placenta 10	maternal morbidity 137
of infant in placenta accreta	injuries and ventouse delivery 5	near miss data collection in 148
255	blood component administration 38	planned home deliveries in 572
use in Japan 171	blood loss,	severe acute maternal morbidity in
arteriovenous malformations 495	accurate estimation,	501, 506
artery, see specific arteries by name	BRASSS-V drape 81, 84–6,	carbetocin 102, 361–7
Asia, severe acute maternal morbidity in	134, 557	cf oxytocin 362, 363
501	reduced severe acute maternal	cf Syntometrine 363
atony, see uterine atony		comparison of studies 363
	morbidity and 508	contraindications 364
Australia,	assessing 73	cost-effectiveness 366
accurate PPH rate determination 152	assessment pitfalls 81–86	
hysterectomy for secondary PPH in	before and after anti-shock garment	current role as uterotonic 366
470	use 335	pharmacology 361
maternal morbidity 137	calibrated drapes cf visual assessment	side-effects 364, 366
severe acute maternal morbidity in	86	use at cesarean section 362
507	causes of excessive 448	use at vaginal delivery 363
autologous blood transfusions 577–82	classification of PPH based on 129	carboprost,
use in Jehovah's Witnesses 590	clinical estimation 82	for uterine atony 357
autopsy,	determination and comparison of	side-effects 357
after PPH 496	studies 133	cardiac output measurement 521
litigation after lack of 532	direct collection of 83–6	care plan for women in labor refusing
	during placenta accreta surgery 268	blood transfusion 597
	estimation from kanga 83, 353, 557	blood transfusion 597 case reports 546–8
B-Lynch compression suture,		
B-Lynch compression suture, FIGO guidelines on 616	estimation from kanga 83, 353, 557	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6
,	estimation from kanga 83, 353, 557 in active management of expectant	case reports 546–8 abdominal pregnancy hemorrhage
FIGO guidelines on 616 technique 434–6, 438	estimation from kanga 83, 353, 557 in active management cf expectant 105	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96	estimation from kanga 83, 353, 557 in active management cf expectant 105 inaccurate estimation and maternal	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6
FIGO guidelines on 616 technique 434–6, 438	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372 mechanism of action 373 method of insertion 390	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock garments in 319	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76 cervix, endocervical tear 491
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372 mechanism of action 373	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock garments in 319 non-pneumatic anti-shock garment	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76 cervix, endocervical tear 491 postpartum pathology of 490
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372 mechanism of action 373 method of insertion 390 methodological parameters of use 389	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock garments in 319 non-pneumatic anti-shock garment for 318, 337	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76 cervix, endocervical tear 491 postpartum pathology of 490 priming with misoprostol 279
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372 mechanism of action 373 method of insertion 390 methodological parameters of use 389 quality Doppler profile 92	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock garments in 319 non-pneumatic anti-shock garment for 318, 337 normal loss during delivery 81	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76 cervix, endocervical tear 491 postpartum pathology of 490 priming with misoprostol 279 tears 194
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372 mechanism of action 373 method of insertion 390 methodological parameters of use 389 quality Doppler profile 92 selection of 372	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock garments in 319 non-pneumatic anti-shock garment for 318, 337 normal loss during delivery 81 physiological adaptations for 82	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76 cervix, endocervical tear 491 postpartum pathology of 490 priming with misoprostol 279 tears 194 repair 195, 197
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372 mechanism of action 373 method of insertion 390 methodological parameters of use 389 quality Doppler profile 92 selection of 372 study results with 371	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock garments in 319 non-pneumatic anti-shock garment for 318, 337 normal loss during delivery 81 physiological adaptations for 82 rapidity 129	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76 cervix, endocervical tear 491 postpartum pathology of 490 priming with misoprostol 279 tears 194 repair 195, 197 cesarean section,
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372 mechanism of action 373 method of insertion 390 methodological parameters of use 389 quality Doppler profile 92 selection of 372 study results with 371 success rate 391	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock garments in 319 non-pneumatic anti-shock garment for 318, 337 normal loss during delivery 81 physiological adaptations for 82 rapidity 129 visual estimation 71	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76 cervix, endocervical tear 491 postpartum pathology of 490 priming with misoprostol 279 tears 194 repair 195, 197 cesarean section, and PPH risk 141
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372 mechanism of action 373 method of insertion 390 methodological parameters of use 389 quality Doppler profile 92 selection of 372 study results with 371 success rate 391 balloon tamponade 369–75	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock garments in 319 non-pneumatic anti-shock garment for 318, 337 normal loss during delivery 81 physiological adaptations for 82 rapidity 129 visual estimation 71 volume deficit 130	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76 cervix, endocervical tear 491 postpartum pathology of 490 priming with misoprostol 279 tears 194 repair 195, 197 cesarean section, and PPH risk 141 bleeding from uterine incision 449
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372 mechanism of action 373 method of insertion 390 methodological parameters of use 389 quality Doppler profile 92 selection of 372 study results with 371 success rate 391 balloon tamponade 369–75 balloon—uterus interface 374	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock garments in 319 non-pneumatic anti-shock garment for 318, 337 normal loss during delivery 81 physiological adaptations for 82 rapidity 129 visual estimation 71 volume deficit 130 blood mat 354, 558	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76 cervix, endocervical tear 491 postpartum pathology of 490 priming with misoprostol 279 tears 194 repair 195, 197 cesarean section, and PPH risk 141 bleeding from uterine incision 449 carbetocin use at 362
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372 mechanism of action 373 method of insertion 390 methodological parameters of use 389 quality Doppler profile 92 selection of 372 study results with 371 success rate 391 balloon tamponade 369–75 balloon—uterus interface 374 complications 409	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock garments in 319 non-pneumatic anti-shock garment for 318, 337 normal loss during delivery 81 physiological adaptations for 82 rapidity 129 visual estimation 71 volume deficit 130 blood mat 354, 558 blood products, see transfusion	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76 cervix, endocervical tear 491 postpartum pathology of 490 priming with misoprostol 279 tears 194 repair 195, 197 cesarean section, and PPH risk 141 bleeding from uterine incision 449 carbetocin use at 362 causes of excessive bleeding during
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372 mechanism of action 373 method of insertion 390 methodological parameters of use 389 quality Doppler profile 92 selection of 372 study results with 371 success rate 391 balloon tamponade 369–75 balloon—uterus interface 374 complications 409 devices for obstetric hemorrhage	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock garments in 319 non-pneumatic anti-shock garment for 318, 337 normal loss during delivery 81 physiological adaptations for 82 rapidity 129 visual estimation 71 volume deficit 130 blood mat 354, 558 blood products, see transfusion blood supply,	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76 cervix, endocervical tear 491 postpartum pathology of 490 priming with misoprostol 279 tears 194 repair 195, 197 cesarean section, and PPH risk 141 bleeding from uterine incision 449 carbetocin use at 362 causes of excessive bleeding during 448
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372 mechanism of action 373 method of insertion 390 methodological parameters of use 389 quality Doppler profile 92 selection of 372 study results with 371 success rate 391 balloon tamponade 369–75 balloon—uterus interface 374 complications 409 devices for obstetric hemorrhage equipment tray 315	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock garments in 319 non-pneumatic anti-shock garment for 318, 337 normal loss during delivery 81 physiological adaptations for 82 rapidity 129 visual estimation 71 volume deficit 130 blood mat 354, 558 blood products, see transfusion blood supply, S1 and S2 in placental invasion 267	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76 cervix, endocervical tear 491 postpartum pathology of 490 priming with misoprostol 279 tears 194 repair 195, 197 cesarean section, and PPH risk 141 bleeding from uterine incision 449 carbetocin use at 362 causes of excessive bleeding during 448 classical 451
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372 mechanism of action 373 method of insertion 390 methodological parameters of use 389 quality Doppler profile 92 selection of 372 study results with 371 success rate 391 balloon tamponade 369–75 balloon—uterus interface 374 complications 409 devices for obstetric hemorrhage equipment tray 315 FIGO guidelines on 615	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock garments in 319 non-pneumatic anti-shock garment for 318, 337 normal loss during delivery 81 physiological adaptations for 82 rapidity 129 visual estimation 71 volume deficit 130 blood mat 354, 558 blood products, see transfusion blood supply, S1 and S2 in placental invasion 267 uterovaginal 19–23	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76 cervix, endocervical tear 491 postpartum pathology of 490 priming with misoprostol 279 tears 194 repair 195, 197 cesarean section, and PPH risk 141 bleeding from uterine incision 449 carbetocin use at 362 causes of excessive bleeding during 448 classical 451 combating hemorrhage during
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372 mechanism of action 373 method of insertion 390 methodological parameters of use 389 quality Doppler profile 92 selection of 372 study results with 371 success rate 391 balloon tamponade 369–75 balloon—uterus interface 374 complications 409 devices for obstetric hemorrhage equipment tray 315 FIGO guidelines on 615 mechanism of action 373	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock garments in 319 non-pneumatic anti-shock garment for 318, 337 normal loss during delivery 81 physiological adaptations for 82 rapidity 129 visual estimation 71 volume deficit 130 blood mat 354, 558 blood products, see transfusion blood supply, S1 and S2 in placental invasion 267 uterovaginal 19–23 blood transfusion, see transfusion	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76 cervix, endocervical tear 491 postpartum pathology of 490 priming with misoprostol 279 tears 194 repair 195, 197 cesarean section, and PPH risk 141 bleeding from uterine incision 449 carbetocin use at 362 causes of excessive bleeding during 448 classical 451 combating hemorrhage during 448–57
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372 mechanism of action 373 method of insertion 390 methodological parameters of use 389 quality Doppler profile 92 selection of 372 study results with 371 success rate 391 balloon tamponade 369–75 balloon—uterus interface 374 complications 409 devices for obstetric hemorrhage equipment tray 315 FIGO guidelines on 615 mechanism of action 373 occlusion by 404	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock garments in 319 non-pneumatic anti-shock garment for 318, 337 normal loss during delivery 81 physiological adaptations for 82 rapidity 129 visual estimation 71 volume deficit 130 blood mat 354, 558 blood products, see transfusion blood supply, S1 and S2 in placental invasion 267 uterovaginal 19–23 blood transfusion, see transfusion blood volume 73	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76 cervix, endocervical tear 491 postpartum pathology of 490 priming with misoprostol 279 tears 194 repair 195, 197 cesarean section, and PPH risk 141 bleeding from uterine incision 449 carbetocin use at 362 causes of excessive bleeding during 448 classical 451 combating hemorrhage during 448–57 elective,
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372 mechanism of action 373 method of insertion 390 methodological parameters of use 389 quality Doppler profile 92 selection of 372 study results with 371 success rate 391 balloon tamponade 369–75 balloon—uterus interface 374 complications 409 devices for obstetric hemorrhage equipment tray 315 FIGO guidelines on 615 mechanism of action 373 occlusion by 404 placement of 408	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock garments in 319 non-pneumatic anti-shock garment for 318, 337 normal loss during delivery 81 physiological adaptations for 82 rapidity 129 visual estimation 71 volume deficit 130 blood mat 354, 558 blood products, see transfusion blood supply, S1 and S2 in placental invasion 267 uterovaginal 19–23 blood transfusion, see transfusion blood volume 73 blunt abdominal trauma 189–91	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76 cervix, endocervical tear 491 postpartum pathology of 490 priming with misoprostol 279 tears 194 repair 195, 197 cesarean section, and PPH risk 141 bleeding from uterine incision 449 carbetocin use at 362 causes of excessive bleeding during 448 classical 451 combating hemorrhage during 448–57 elective, and PPH 156
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372 mechanism of action 373 method of insertion 390 methodological parameters of use 389 quality Doppler profile 92 selection of 372 study results with 371 success rate 391 balloon tamponade 369–75 balloon–uterus interface 374 complications 409 devices for obstetric hemorrhage equipment tray 315 FIGO guidelines on 615 mechanism of action 373 occlusion by 404 placement of 408 pressure–volume relationships 374	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock garments in 319 non-pneumatic anti-shock garment for 318, 337 normal loss during delivery 81 physiological adaptations for 82 rapidity 129 visual estimation 71 volume deficit 130 blood mat 354, 558 blood products, see transfusion blood supply, S1 and S2 in placental invasion 267 uterovaginal 19–23 blood transfusion, see transfusion blood volume 73 blunt abdominal trauma 189–91 body mass index (BMI),	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76 cervix, endocervical tear 491 postpartum pathology of 490 priming with misoprostol 279 tears 194 repair 195, 197 cesarean section, and PPH risk 141 bleeding from uterine incision 449 carbetocin use at 362 causes of excessive bleeding during 448 classical 451 combating hemorrhage during 448–57 elective, and PPH 156 for adherent placenta 10
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372 mechanism of action 373 method of insertion 390 methodological parameters of use 389 quality Doppler profile 92 selection of 372 study results with 371 success rate 391 balloon tamponade 369–75 balloon–uterus interface 374 complications 409 devices for obstetric hemorrhage equipment tray 315 FIGO guidelines on 615 mechanism of action 373 occlusion by 404 placement of 408 pressure–volume relationships 374 uterine–specific of non–specific	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock garments in 319 non-pneumatic anti-shock garment for 318, 337 normal loss during delivery 81 physiological adaptations for 82 rapidity 129 visual estimation 71 volume deficit 130 blood mat 354, 558 blood products, see transfusion blood supply, S1 and S2 in placental invasion 267 uterovaginal 19–23 blood transfusion, see transfusion blood volume 73 blunt abdominal trauma 189–91 body mass index (BMI), external abdominal pressure and 336	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76 cervix, endocervical tear 491 postpartum pathology of 490 priming with misoprostol 279 tears 194 repair 195, 197 cesarean section, and PPH risk 141 bleeding from uterine incision 449 carbetocin use at 362 causes of excessive bleeding during 448 classical 451 combating hemorrhage during 448–57 elective, and PPH 156 for adherent placenta 10 PPH after 7
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372 mechanism of action 373 method of insertion 390 methodological parameters of use 389 quality Doppler profile 92 selection of 372 study results with 371 success rate 391 balloon tamponade 369–75 balloon–uterus interface 374 complications 409 devices for obstetric hemorrhage equipment tray 315 FIGO guidelines on 615 mechanism of action 373 occlusion by 404 placement of 408 pressure–volume relationships 374 uterine-specific of non-specific balloons 387	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock garments in 319 non-pneumatic anti-shock garment for 318, 337 normal loss during delivery 81 physiological adaptations for 82 rapidity 129 visual estimation 71 volume deficit 130 blood mat 354, 558 blood products, see transfusion blood supply, S1 and S2 in placental invasion 267 uterovaginal 19–23 blood transfusion, see transfusion blood volume 73 blunt abdominal trauma 189–91 body mass index (BMI), external abdominal pressure and 336 PPH incidence and 156	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76 cervix, endocervical tear 491 postpartum pathology of 490 priming with misoprostol 279 tears 194 repair 195, 197 cesarean section, and PPH risk 141 bleeding from uterine incision 449 carbetocin use at 362 causes of excessive bleeding during 448 classical 451 combating hemorrhage during 448–57 elective, and PPH 156 for adherent placenta 10 PPH after 7 timing of 438
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372 mechanism of action 373 method of insertion 390 methodological parameters of use 389 quality Doppler profile 92 selection of 372 study results with 371 success rate 391 balloon tamponade 369–75 balloon–uterus interface 374 complications 409 devices for obstetric hemorrhage equipment tray 315 FIGO guidelines on 615 mechanism of action 373 occlusion by 404 placement of 408 pressure–volume relationships 374 uterine-specific of non–specific balloons 387 uterine specific 369	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock garments in 319 non-pneumatic anti-shock garment for 318, 337 normal loss during delivery 81 physiological adaptations for 82 rapidity 129 visual estimation 71 volume deficit 130 blood mat 354, 558 blood products, see transfusion blood supply, S1 and S2 in placental invasion 267 uterovaginal 19–23 blood transfusion, see transfusion blood volume 73 blunt abdominal trauma 189–91 body mass index (BMI), external abdominal pressure and 336 PPH incidence and 156 PPH risk and 139	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76 cervix, endocervical tear 491 postpartum pathology of 490 priming with misoprostol 279 tears 194 repair 195, 197 cesarean section, and PPH risk 141 bleeding from uterine incision 449 carbetocin use at 362 causes of excessive bleeding during 448 classical 451 combating hemorrhage during 448–57 elective, and PPH 156 for adherent placenta 10 PPH after 7 timing of 438 emergency
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372 mechanism of action 373 method of insertion 390 methodological parameters of use 389 quality Doppler profile 92 selection of 372 study results with 371 success rate 391 balloon tamponade 369–75 balloon–uterus interface 374 complications 409 devices for obstetric hemorrhage equipment tray 315 FIGO guidelines on 615 mechanism of action 373 occlusion by 404 placement of 408 pressure–volume relationships 374 uterine-specific of non–specific balloons 387 uterine specific 369 uterovaginal balloon system	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock garments in 319 non-pneumatic anti-shock garment for 318, 337 normal loss during delivery 81 physiological adaptations for 82 rapidity 129 visual estimation 71 volume deficit 130 blood mat 354, 558 blood products, see transfusion blood supply, S1 and S2 in placental invasion 267 uterovaginal 19–23 blood transfusion, see transfusion blood volume 73 blunt abdominal trauma 189–91 body mass index (BMI), external abdominal pressure and 336 PPH incidence and 156 PPH risk and 139 bowel obstruction and fibrin sealants 484	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76 cervix, endocervical tear 491 postpartum pathology of 490 priming with misoprostol 279 tears 194 repair 195, 197 cesarean section, and PPH risk 141 bleeding from uterine incision 449 carbetocin use at 362 causes of excessive bleeding during 448 classical 451 combating hemorrhage during 448–57 elective, and PPH 156 for adherent placenta 10 PPH after 7 timing of 438 emergency for unexpected adherent
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372 mechanism of action 373 method of insertion 390 methodological parameters of use 389 quality Doppler profile 92 selection of 372 study results with 371 success rate 391 balloon tamponade 369–75 balloon–uterus interface 374 complications 409 devices for obstetric hemorrhage equipment tray 315 FIGO guidelines on 615 mechanism of action 373 occlusion by 404 placement of 408 pressure–volume relationships 374 uterine-specific of non–specific balloons 387 uterine specific 369 uterovaginal balloon system 458–460	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock garments in 319 non-pneumatic anti-shock garment for 318, 337 normal loss during delivery 81 physiological adaptations for 82 rapidity 129 visual estimation 71 volume deficit 130 blood mat 354, 558 blood products, see transfusion blood supply, S1 and S2 in placental invasion 267 uterovaginal 19–23 blood transfusion, see transfusion blood volume 73 blunt abdominal trauma 189–91 body mass index (BMI), external abdominal pressure and 336 PPH incidence and 156 PPH risk and 139 bowel obstruction and fibrin sealants 484 Brace suture technique 433, 452	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76 cervix, endocervical tear 491 postpartum pathology of 490 priming with misoprostol 279 tears 194 repair 195, 197 cesarean section, and PPH risk 141 bleeding from uterine incision 449 carbetocin use at 362 causes of excessive bleeding during 448 classical 451 combating hemorrhage during 448–57 elective, and PPH 156 for adherent placenta 10 PPH after 7 timing of 438 emergency for unexpected adherent placenta 11
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372 mechanism of action 373 method of insertion 390 methodological parameters of use 389 quality Doppler profile 92 selection of 372 study results with 371 success rate 391 balloon tamponade 369–75 balloon–uterus interface 374 complications 409 devices for obstetric hemorrhage equipment tray 315 FIGO guidelines on 615 mechanism of action 373 occlusion by 404 placement of 408 pressure–volume relationships 374 uterine-specific of non-specific balloons 387 uterine specific 369 uterovaginal balloon system 458–460 Bangladesh,	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock garments in 319 non-pneumatic anti-shock garment for 318, 337 normal loss during delivery 81 physiological adaptations for 82 rapidity 129 visual estimation 71 volume deficit 130 blood mat 354, 558 blood products, see transfusion blood supply, S1 and S2 in placental invasion 267 uterovaginal 19–23 blood transfusion, see transfusion blood volume 73 blunt abdominal trauma 189–91 body mass index (BMI), external abdominal pressure and 336 PPH incidence and 156 PPH risk and 139 bowel obstruction and fibrin sealants 484 Brace suture technique 433, 452 bradykinin 581	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76 cervix, endocervical tear 491 postpartum pathology of 490 priming with misoprostol 279 tears 194 repair 195, 197 cesarean section, and PPH risk 141 bleeding from uterine incision 449 carbetocin use at 362 causes of excessive bleeding during 448 classical 451 combating hemorrhage during 448–57 elective, and PPH 156 for adherent placenta 10 PPH after 7 timing of 438 emergency for unexpected adherent placenta 11 PPH in first stage of labor 8
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372 mechanism of action 373 method of insertion 390 methodological parameters of use 389 quality Doppler profile 92 selection of 372 study results with 371 success rate 391 balloon tamponade 369–75 balloon–uterus interface 374 complications 409 devices for obstetric hemorrhage equipment tray 315 FIGO guidelines on 615 mechanism of action 373 occlusion by 404 placement of 408 pressure–volume relationships 374 uterine-specific of non-specific balloons 387 uterine specific 369 uterovaginal balloon system 458–460 Bangladesh, blood loss assessment by mat 354,	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock garments in 319 non-pneumatic anti-shock garment for 318, 337 normal loss during delivery 81 physiological adaptations for 82 rapidity 129 visual estimation 71 volume deficit 130 blood mat 354, 558 blood products, see transfusion blood supply, S1 and S2 in placental invasion 267 uterovaginal 19–23 blood transfusion, see transfusion blood volume 73 blunt abdominal trauma 189–91 body mass index (BMI), external abdominal pressure and 336 PPH incidence and 156 PPH risk and 139 bowel obstruction and fibrin sealants 484 Brace suture technique 433, 452 bradykinin 581 brain size,	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76 cervix, endocervical tear 491 postpartum pathology of 490 priming with misoprostol 279 tears 194 repair 195, 197 cesarean section, and PPH risk 141 bleeding from uterine incision 449 carbetocin use at 362 causes of excessive bleeding during 448 classical 451 combating hemorrhage during 448–57 elective, and PPH 156 for adherent placenta 10 PPH after 7 timing of 438 emergency for unexpected adherent placenta 11 PPH in first stage of labor 8 European consensus on prevention
FIGO guidelines on 616 technique 434–6, 438 Bakri balloon 369, 370, 378, 379, 387–96 deflation regimen 391 insertion 372 mechanism of action 373 method of insertion 390 methodological parameters of use 389 quality Doppler profile 92 selection of 372 study results with 371 success rate 391 balloon tamponade 369–75 balloon–uterus interface 374 complications 409 devices for obstetric hemorrhage equipment tray 315 FIGO guidelines on 615 mechanism of action 373 occlusion by 404 placement of 408 pressure–volume relationships 374 uterine-specific of non-specific balloons 387 uterine specific 369 uterovaginal balloon system 458–460 Bangladesh,	estimation from kanga 83, 353, 557 in active management of expectant 105 inaccurate estimation and maternal mortality 164 measurement of and comparison of studies 134 mechanism of action of anti-shock garments in 319 non-pneumatic anti-shock garment for 318, 337 normal loss during delivery 81 physiological adaptations for 82 rapidity 129 visual estimation 71 volume deficit 130 blood mat 354, 558 blood products, see transfusion blood supply, S1 and S2 in placental invasion 267 uterovaginal 19–23 blood transfusion, see transfusion blood volume 73 blunt abdominal trauma 189–91 body mass index (BMI), external abdominal pressure and 336 PPH incidence and 156 PPH risk and 139 bowel obstruction and fibrin sealants 484 Brace suture technique 433, 452 bradykinin 581	case reports 546–8 abdominal pregnancy hemorrhage treatment 583–6 catheterization routes 408 cell salvage use in Jehovah's Witnesses 590 central venous pressure 75, 76 cervix, endocervical tear 491 postpartum pathology of 490 priming with misoprostol 279 tears 194 repair 195, 197 cesarean section, and PPH risk 141 bleeding from uterine incision 449 carbetocin use at 362 causes of excessive bleeding during 448 classical 451 combating hemorrhage during 448–57 elective, and PPH 156 for adherent placenta 10 PPH after 7 timing of 438 emergency for unexpected adherent placenta 11 PPH in first stage of labor 8

for placents accreas 242-46 find placents previa 234-35 findal route 11, 12 previous and risk of placents previa 231 stee of excreas reaction and risk of placents previa 231 stee of excreas very 182 ruid of labor after 189-55 mindal for first 189-55 mindal for first 189-55 mindal for first 189-55 mindal for after 189-55 mindal for first 189	for placanta accrete 242 4	callaids for valums averagion 77	costs
construct 11, 12 and 247 pPH in miderate and 247 pPH miderate and 156 previous and risk of placenta several sections for 449–51 uterine reputer and previous 188 with byservectomy for placenta accreta 242 bring the common declared higharon. 446 common discard higharon 446 common like afters, you image 6 common win, damage to during a carca 242 bring the common windered higharon. 446 common like afters, you image 6 common win, damage to during a carca 242 bring the common windered higharon. 446 common like afters, you image 6 common win, damage to during a carca 242 bring to 559 effective 552 peffective 552 peffective 552 peffective 559 effective 552 peffective 552 peffective 552 peffective 552 peffective 552 peffective 552 peffective 553 performance and 156 pPPH risk and 143 problems 453 pPPI incidence and 156 pPPH risk and 143 problems 453 pPPI middence and 156 pPPH risk and 143 problems 453 pPPI middence and 156 pPPH risk and 143 problems 453 pPPI middence and 156 pPPH risk and 143 problems 453 pPPI middence and 156 pPPH risk and 143 proposed. 136 passed on custative factor 130 conventional temporal 129 of beaded on custative factors 130 conventional temporal 129 proposed 136 propo			
lack of surgical competency 163 placents acreate michages and 156 previous and risk of placents previa site of exessive bleeding during risk of laker after 189 uterian insists of placents accreted 242 wound define from 190 blood control from 190 blood		1	
pakenta accreta incidence and 147 PPH incidence and 156 previous and risk of placenta previa 231 sites of excessive bleeding during site of ex			
pPFII incidence and 156 previous and risk of placental previal 231 previous and risk of placental previal 248 trial of labor after 189 treatment previal 448 trial of labor after 189 treatment previous 188 with trial of labor after 189 treatment previous 188 with trial of labor after 189 treatment previous 188 with trial of labor after 189 treatment previous 188 with trial of labor after 189 treatment previous 188 with trial of labor after 189 treatment previous 188 with trial of labor after 189 treatment previous 188 with trial of labor after 189 treatment previous 189 treatment previous 184 trial of labor after 189 trial of labor after 189 treatment previous 184 trial of labor after 189 trial of			
previous and risk of placenta previa 231 sits of excessive beleding during 448 rial of labor after 189 uterian encision for 449–51 uterian encision for 40–51 uterian encision for 449–51 uterian encision for 449–61 uterian encision for 49–61 uterian encision for 449–61 uterian encision for 449–61 uterian encision for 49–61 uterian encision for 449–61 uterian encision for 49–61 uteria			
231 214 324 325 326, 287, 358 36 suggrey 341 326 for training for tensmort 55 5 common liae artery, avoidance of accidental ligation 446 5 common liae artery, avoidance of accidental ligation 446 5 common liae artery, avoidance of accidental ligation 446 5 common liae artery, avoidance of accidental ligation 446 5 common liae artery, avoidance of accidental ligation 446 5 common liae artery, avoidance of accidental ligation 446 5 common liae artery, avoidance of accidental ligation 446 5 common liae artery, avoidance of accidental ligation 446 6 common liae artery,			
sites of excessive bleeding during 448 trial of labor after 189 tuterine incision for 449–51 uterine incision for 449–51 uterine response and previous 188 with hysterectomy for placenta accreta 242 wound decharactic 467 checklist for women in labor refusing chemotherapy for obtonic-actionoma 471 chitrengue and blood loss assessment 354 Cho compersions stutre, FIGO guidelines on 616 multiple square sutures 438 chorioraminonist 433 PPHI nicidence and 156 PPH risk and 143 chorioractinions, chemotherapy for 471 secondary PPII and 467 chronic uterine inversion 188 creation for 57 Pepleralization for 57 replications, based on blood loss 129 based on causative factors 130 conventional temporal 129 of beleeting from lower genital tract 1929 and PPH risk 140 and PPH risk 140 approfered disorders of hemostasis quired disorders of hemos		•	
448 acadeatal ligation 446 common tital chalor A-real pinage of training for teamwork 565 of utertonics 1015 of training for teamwork 565 of utertonics 1016 or under the problems and material morbidity and mortality 166 in development in order of the mortality 166 in development of the problems and material morbidity and mortality 308, 209 community. Seed on circular 30 of the problems and material morbidity and mortality 308, 209 community 308, 209			
trait of labor after 189 tuerine microism for 449–51 uterine rupture and previous 188 with hysterectomy for placents accrete 242 wound dehisecnee. 467 effectives 522 improvements in to reduce maternal placent accrete 251 commands and surface and 156 pm through a mortality 166 in development of hospital systems for PPH 1 microlene and 156 pm HPH miss and 143 problems and maternal mobilization for continuum of care 555 pm HPH six and 143 pm HPH miss and 143 community. Level 353 community, bend contactivitions, and 143 conventional temporal 129 concluding your poposed. 131 conventional temporal 129 of bleeding from lower genital ract 193 conjudication cascade 481 congulation of spacental size 96 congulation or spacent changes during pregnancy 199 congulopathy 3, 78 acquired disorders of hemostasis 199–204 and PPH 1 sk 140 as part of 14ch thronical proposed 131 conventional temporal 129 congulation at placental size 96 congulation or spaced with proposed 131 conventional proposed 131 conventional temporal 242 consumptive 204–8 in placental size 96 congulation or spaced 481 congenital arteriorenous mildiornations 166 confidential Enquiry into Maternal and Cohld Health, 140 consumptive 204–8 in pregnancy 199 congulopathy 3, 78 acquired disorders of hemostasis 199–204 and PPH 1 risk 140 consumptive 204–8 in pregnancy 199 congulopathy 3, 78 acquired disorders of hemostasis 199–204 and pPH 1 risk 140 consumptive 204–8 in pregnancy 199 congulopathy 3, 78 acquired disorders 212–15 recognition of 418 in ableeding from lower genital tract 194 secondary PPH and 467 conductive the confidency and proposed		•	
uterien entorien and previous 188 with hysterectomy for placenta accreta 242 bypogastria ratery ligation 446 communication, bypogastria ratery ligation, deficit 261 communication, bypogastria ratery ligation 446 communication, bypogastria rateries to 59 ceffective 552 in mortality 166 in development of hospital yietems in to reduce maternal morbidity and mortality 166 in development of to hoppital disveries 571— problems and materal morbidity and minority 166 of morbidity and minority 166 in development of communication of consuminosis 433 problems and material roommunication of communication of community 208, 309 community, 208 conformation for continuum of care community, 208, 309 community, 208 conformation for continuum of care community, 208, 309 community, 208 conformation for continuum of care community, 208, 309 community, 208 conformation for continuum of care community, 208, 309 community, 208 conformation for continuum of care comm			
with hysterectomy for placeta with hyspocestric artery ligation 446 considerate with hysterectomy for placeta accreta 242 wound debisence 467 checklist for women in labor refusing blood transfusion 599 chemotherapy for chorolecarcinoma 471 chiefled part of the properties and maternal morbidity and morathy 308, 309 community. How and morathy 308, 309 community were stated to the properties of the properties and maternal morbidity and morathy 308, 309 community. How and the properties are the properties of the properties are the properties of the properties and maternal morbidity and morathy 308, 309 community. How and the properties are the properties are the properties of the properties are the properties of the properties and maternal morbidity and morathy 308, 309 community. How and the properties are the properties are the properties of the properties are the properties of the properties and morbidity and maternal morbidity and morathy 308, 309 community. He are the properties are the properties of			
with hysterectomy for placenta accreta 242 barriers to 559 effective 552 improvements in the return of the content of the cont			
accreta 242 wound dehience 467 checklist for women in labor refusing blood transfusion 599 chemotherapy for choriocarcinoma 471 Cho compression suture, FIGO guidelines on 616 multiple square sutures 438 chorionaministis 453 PPH nicidence and 156 PPH six and 143 chorionacrinoma, 471 chemotherapy for 472 chemotherapy for 471 chemotherapy for 473 chemotherapy for 471 chemotherapy for 472 chemotherapy for 471 chemotherapy for 472 chemotherapy for 471 chemotherapy for 471 chemotherapy for 472 chemotherapy for 471 chemotherapy for 471 chemotherapy for 472 chemotherapy for 471 chemotherapy for 471 chemotherapy for 472 chemotherapy for 471 chemotherapy for 471 chemotherapy for 47			
wound dehiscence 467 checklist for women in labor refusing blood transfusion 599 chemotherapy for cheriocarcinoma 471 chittengue and blood loss assessment 354 Cho compression suture, FIGO gaidelines on 616 multiple sparse sutures 438 chorioaminoinis 453 PPH risk and 143 choriocarcinoma, chemotherapy for 471 secondary PPH and 467 chronic turtine inversion 188 circulating volume 73-9 assessment of 73 replenishment of 77 circulationy management 521 classifications, based on blood loss 129 based on causative factors 130 conventional temporal 129 of Delecting from lower genital tract port of PPH 32 piffalls 131 roune deficit 30 compression at placental site 96 coagulation as placental site 96 coagulation or seaced 481 coagulation or seaced 4		· · · · · · · · · · · · · · · · · · ·	
checklist for women in labor refusing blood transfusion 599 chemotherapy for choriocarcinoma 471 chirengue and blood lows assessment 354 chorioamnionits 453 moltiple square sutures 438 circulating volume 73-9 secondary PPH and 467 consumptive replenishment of 77 circulatory management 521 classifications, based on blood loss 129 based on causative factors 130 conventional temporal 129 of bleeding from lower genital tract 193 morposed 131 volume deficit 130 proposed 131 congulation oxygenetherages during pregnancy 199 congulation are placental size 96 congulation oxygenetherage sturing pregnancy 199 congulation and abruption 229 in pregnant Jehovah's Witnesses 589 in secondary PPH 471 management of 46 management of 47 more proposed 141 minute 194 secondary PPH 471 more proposed 142 minute 144 secondary PPH 471 management of 46 management of 47 more proposed 148 more propos			
blood transfusion 599 chemotherapy for choriocarcinoma 471 chittengue and blood loss assessment 354 Cho compression stuture. FIGO guidelines on 616 multiple square sutures 438 chorioamionitis 453 PPH risk and 143 choriocarcinoma, chemotherapy for 471 secondary PPH and 467 choriotic turcine inversion 188 circulating volume 73-9 assessment of 73 replenishment of 57 circulatory management 521 classifications, based on blood loss 129 based on causative factors 130 conventional temporal 129 of bleeding from lower genital tract 193 of PPH 82 pitfalk 130 proposed 131 volume deficit 130 congulation or space and aboration system changes during pregramacy 199 cogatilonis viscacia 481 congulation in spacental aboration 229 in pregonal pehovah's Witneses 589 in secondary PPH 471 management of 46 matterall mortality 164 of sepsis 485 race disorders of themostasis 199-204 and PPH risk 140 as part of 'lebtal triad' 24 consumptive 204-8 in obsteric hemorrhage 415 on placental aboration 229 in pregnant plehovah's Witneses 589 in secondary PPH 471 management of 46 matterall mortality 164 of sepsis 485 race disorders of hemostasis tract 194 secondary PPH and 467 see also by specific disorder coil deployment in non-targeted embolization for continuum of care 555-60 out-of-hospital deliveries 571-4 PPH management at community level 353 cont-of-hospital deliveries 571-4 PPH management of acre 555-60 out-of-hospital deliveries 571-4 FIGO guidelines on 612 cogulation of continuum of care 555-60 community-based entergency care 542 FIGO guidelines on 612 cogulation of section 432 surgical amanagement of placenta accreta surgery 204 deep vein thrombosis after placenta accreta surgery 205 disters, 555-60 compension of placenta accreta 252 diste			
chemotherapy for choriocarcinoma 471 Cho compression suture, FIGO guidelines on 616 multiple square sutures 438 chorioamnionitis 453 PPH incidence and 156 PPH risk and 143 chorioacrcinoma. 871 secondary PPH and 467 chronic uterine inversion 188 circulating volume 73-9 assessment of 73 replenishment of 77 circulatory management 521 classifications, based on blood loss 129 based on custative factors 130 conventional temporal 129 of bleeding from lower genital tract 193 corposed 131 conventional temporal 129 of PPH 82 pitfalls 130 conventional temporal 129 of PPH 82 pitfalls 130 conventional temporal 129 coagulation at placental size 96 coagulation at placental size 96 coagulation at placental size 96 coagulation cascade 481 coagulation cascade 481 as part of Ptehal triad 24 consumptive 204-8 in obsectric hemorrhage 415 in placental abruption 229 coaguloapty 3, 78 acquired disorders of hemostasis 199-204 and PPH risk 140 as part of Ptehal triad 24 consumptive 204-8 in obsectric hemorrhage 415 in placental abruption 229 in pregnanty 199 coaguloapty 3, 78 acquired disorders of hemostasis 199-204 and PPH risk 140 as part of Ptehal triad 24 consumptive 204-8 in obsectric hemorrhage 415 in placental abruption 229 in pregnanty 199 coaguloapty 3, 78 acquired disorders of hemostasis 199-204 and PPH risk 140 as part of Ptehal triad 24 consumptive 204-8 in obsectric hemorrhage 415 in placental abruption 229 in pregnanty 199 coaguloapty 3, 78 acquired disorders of hemostasis 199-204 and PPH risk 140 osservative surgery 43-44 consumptive 204-8 in obsectric hemorrhage 415 in placental abruption 229 in pregnanty 199 coaguloapty 3, 78 acquired disorders of hemostasis 199-204 and PPH risk 140 osservative surgery 43-440 consumptive 204-8 in obsectric hemorrhage 415 in placental abruption 229 in pregnanty 199 coaguloapty 3, 78 acquired disorders of hemostasis 199-204 and PPH risk 140 osservative surgery 43-440 consumptive 204-8 in obsectric hemorrhage 415 in placental abruption 29 in pregnant plowabis Winesees 589 in secondary PPH		*	
chittengue and blood loss assessment 354 Cho compression suture, FIGO guidelines on 616 multiple square sutures 438 chorioaminonitis 453 PPH risk and 143 chemotherapy for 471 secondary PPH rad 467 chronic uternic inversion 188 circulating volume 73-9 assessment 673 replemishment of 77 circulatory management 521 classifications, based on blood loss 129 based on blood loss 129 based on causative factors 130 conventional temporal 129 of bleeding from lower genital tract 193 or PPH 81 orappination are placental site 96 coagulation system changes during pregnancy 199 coagulation system changes during pregnancy 199 coagulation system changes during pregnancy 199 coagulation system changes during as part of lethal triad 24 consumptive 204-8 in obstetic hemorrhage 415 in placental abruption 229 in pregnant plovah's Witnesses 589 in secondary PPH 471 management of 46 maternal mortality 164 of sepsis 485 pathophysiology of 45 rar edisorders 212-15 recognition of 418 in bleeding from lower genital ract 194 secondary PPH and 467 sea blo by specific disorders coil deployment in non-targeted cubble of combinin-fibrinogen patch 485 cullateral arteries 400 collagen-thrombin-fibrinogen patch 485 cullateral arteries 400 for ppen race and ppen r		in development of hospital systems	
Cho compression suture, FIGO guidelines on 616 multiple square sutures 438 chorioamnionitis 453 pPH incidence and 156 pPH risk and 143 choriocarcinoma, chemotherapy for 471 secondary PPH and 467 chronic tuterine inversion 188 crival and mortalisty 308, 309 pPH maka and 143 choriocarcinoma, chemotherapy for 471 secondary PPH and 467 chronic tuterine inversion 188 crival and policy assessment of 73 replenishment of 77 crivaltarory management 521 classifications, based on blood loss 129 based on causative factors 130 conventional temporal 129 assessment of 32 pitched and proposed 131 volume deficit 130 conventional temporal 129 assessment of policy and policy and policy and policy and mortalisty 308, 309 conventional remporal 188 community-based continuum of care 555–60 community. Seed continuum of care 555–60 community based continuum of care 612 competence, 163 community base			
multiple square sutures 438 chorioamionitis 433 PPH inicidence and 156 PPH risk and 143 choriocarcinoma, secondary PPH and 467 chronic utertine inversion 188 circulating volume 73-9 assessment of 73 criculatory management 521 classifications, based on blood loss 129 based on causative factors 130 conventional temporal 129 of bleeding from lower genital tract 193 of PPH 82 pitfalls 130 proposed 131 volume deficit 130 coagulation at placental site 96 coagulation at system changes during pregnancy 199 coagulatorion system changes during pregnancy 199 coagulation system changes during pregnancy 199 coagulation system changes during pregnancy 199 coagulatorion ya, 7, 8 a cquirted disorders of hemostasis 199-204 and PPH risk 140 as part of Pethal triad² 24 consumptive 204-8 in obsterite hemorrhage 415 in placental abruption 229 in pregnant pleboval's Witnesses 589 in secondary PPH 471 management of 46 maternal mortality 164 of sepais 485 pathophysiology of 45 rare disorders 212-15 recognition of 418 in bleeding from lower genital tract 194 secondary PPH and 467 sea bot 9 specific disorders coll deployment in non-targeted enhobitoration 403 collagen-thrombin-fibrinogen patch 483 conventional temporal classification of 616box (continuum of care model 555-60 ountmunity-based continuum of care 575-40 community-based contenuum of care 555-60 community-based contenuum of care 555-60 community-based contenuum of care 575-40 community-based contenuum of care 575-40 community-based contenuum of care 524 community-based contenuum of care 555-60 community-based contenuum of care 555-60 community-based contenuum of care 494 depth value actrea 435 discussionation 47 devacularization, 79 depth 163 litigation over insulficient experience 535 community-based			
multiple square sutures 438 chorioamionisis 433 PPH nicidence and 156 PPH risk and 143 choriocarcinoma,			,
choriocarcinomis, 453 PPH risk and 143 choriocarcinoma, chemotherapy for 471 secondary PPII and 467 chronic uternic inversion 188 circulating volume 73-9 assessment of 73 replenishment of 77 circulatory management 521 classifications. based on blood loss 129 based on causative factors 130 conventional temporal 129 of bleeding from lower genital tract 193 conventional temporal 129 of bleeding from lower genital tract 194 coagulation as placental site 96 coagulation cacade 481 coagulation asystem changes during pregnancy 199 coagulation system changes during pregnancy 199-204 and PPH risk 140 as part of 'lethal triad' 24 consumptive 204-8 in obstetic hemorrhage 415 in placental abruption 229 in pregnant Jehovah's Witnesses 589 in secondary PPI 471 management of 46 maternal mortality 164 of see also by specific disorder coil delpoyment in non-targeted embolization 403 collagen-thrombin-fibrinogen patch 448 collateral actricis 400 mobilization for continuum of care 555-5 out-of-hospital deliveries 571-4 PPH management at community level 353 community-based continuum of care 555-60 community-based continuum of care 555-60 community-based continuum of care 555-60 community-based continuum of care 552 community-based continuum of care 555-60 community-based continuum of care 555-60 community-based continuum of care 552 community-based continuum of care 552 community-based continuum of care 552 community-based continuum of care 555-60 community-based continuum of care 552 competence, 163 litigation over insufficient experience 532 surgeon experience 433 surgical management of placenta accreta surgery 270 definitions 133, 155, 550, 608 depviarion postabor 4 deep vein thrombosis after placenta accreta surgery 270 definitions 133, 155, 550, 608 depviarion post			
PPH incidence and 156 PPH risk and 143 choriocacrinoma,		• •	
out-of-hospital deliveries 571-4 choriocarcinoma, chemotherapy for 471 secondary PPH and 467 chronic uterine inversion 188 circulating volume 73-9 assessment of 73 replenishment of 77 replenishment of 78 passed on blood loss 129 based on causative factors 130 conventional temporal 129 of bleeding from lower genital tract 193 of PPH 82 pitfalls 130 conventional temporal 129 of PPH 82 pitfalls 130 composed 131 volume deficit 130 coagulation on a placental site 96 coagulation on a placental site 96 coagulation on a placental site 96 coagulation on system changes during pregnancy 199 regnancy 199 coagulopathy 3, 78 acquired disorders of hemostasis 199-204 and PPH risk 140 as part of Tethal triad' 24 consumptive 204-8 in obstetric hemorrhage 415 in placental abruption 229 in pregnant Jehovah's Witnesses 589 in secondary PPH 471 management and 467 see also by specific disorder coil deployment in non-targeted coil deployment in non-targeted collateral artract 940 collateral artracts 400 collateral artracts 400 conventionion of 609 collateral artracts 400 conventionion of 609 community-based continuum of care community deemgency care 542 pRFIGO guidelines on 612 community-based continuum of care accreta surgery 270 definitions 133, 155, 550, 608 delphydration postabor 4 devacularization, stepwise 20, 439-40, 452 diabetes, and PPH risk 139 antenatal treatment of 194 dianoptors 388 dinoprostone in first stage management and PPH risk 140 as part of Tethal triad' 24 consumptive 204-8 in obstetric hemorrhage 415 in placental abruption 229 in pregnancy 199 in recondary PPH 471 management of 46 maternal mortality 164 of sepais 485 pathophysiology of 45 rare disorders 210-215 recognition of 418 in bleeding from lower genital tract 194 secondary PPH 471 s			
chemotherapy for 471 secondary PPH and 467 chronic uterine inversion 188 circulating volume 73-9 assessment of 73 replenishment of 77 circulatory management 521 classifications, based on blood loss 129 based on causative factors 130 conventional temporal 129 of bleeding from lower genital tract 193 of PPH 82 of piffalls 130 proposed 131 volume deficit 130 coagulation at placental site 96 coagulation at placental site 96 coagulatony system changes during pregnancy 199 coagulopasty 3, 78 acquired disorders of hemostasis 199-204 and PPH risk 140 as part of 'lethal triad' 24 consumptive 204-8 in obsective hemorrhage 415 in placental abruption 229 in pregnant Jehovah's Witnesses 589 in secondary PPH 471 management of 46 maternal mortality 164 of sepsis 485 pathophysiology of 45 rare disorders 212-15 recognition of 418 in bleeding from lower genital tract 194 secondary PPH and 467 see also by specific disorders coll deployment in non-targeted embilization 403 collagen-thrombin-fibrinogen patch 483 collagen-thrombin-fibrinogen patch 483 collagen-thrombin-fibrinogen patch 483 collagen-thrombin-fibrinogen patch 483 conventional temporal classification of 60 community-based continuum of care 555-60 community-based continuum of care 555-60 community-based continuum of care 555-60 community-based continuum of care 542 FIGO guidelines on 612 competence, 532 surgeon experience 433 surgical management of placenta accreta 453 competence 433 competence 433 competence 433 competence 435 competence 4			
chemotherapy for 471 secondary PPH and 467 chronic uterine inversion 188 circulating volume 73–9 assessment of 73 replenishment of 77 circulatory management 521 classifications, based on blood loss 129 based on causative factors 130 conventional temporal 129 of bleeding from lower genital tract 193 of PPH 82 piffalls 130 composed 131 volume deficit 130 coagulation or aplacental site 96 coagulation at placental site 96 coagulation at placental site 96 coagulation system changes during pregnancy 199–204 and PPH risk 140 as part of 'lethal triad' 24 consumptive 204–8 in obstetric hemorrhage 415 in placental abruption 229 in pregnant Jehoval's Witnesses 589 in secondary PPH 471 management of 46 maternal mortality 164 of sepsis 485 pathophysiology of 45 rare disorders 212–15 recognition of 418 in bleeding from lower genital tract 194 secondary PPH and 467 see also by specific disorder coil delpoyment in non-targeted combolization 403 collagen-thrombin-fibrinogen patch 483 contention terrine inversion 188 community-based continuum of care specific disense mergency care 542 FIGO guidelines on 612 community-based continuum of care specific disense on 612 community-based continuum of care specifications, 622 displacenta, 33, 153, 535, 608 dehydration postabor 4 devactionization, 439 antental treatment of 194 disports 358 dinoprostone in first stage management and PPH 1sk 149 accreta 453 compertioned starcty ligation 457 cf. Cho multiple square sutures 438 Hayman uterine compression sutures 438, 453 concealed PPH 13 Confidential Enquiry into Maternal and		_	in placenta accreta 254
secondary PPH and 467 circulating volume 73–9 assessment of 73 replenishment of 77 circulatory management 521 classifications, based on blood loss 129 of bleeding from lower genital tract 193 of PPH 82 pitfalls 130 proposed 131 volume deficit 130 coagulation at placental site 96 coagulation aspace change during pregnancy 199 coagulation system changes during pregnancy 199 coagulopathy 3, 78 acquired disorders of hemostasis 199–204 and PPH risk 140 as part of 'tehal triad' 24 consumptive 204–8 in obstetric hemorrhage 415 in placental abruption 229 in pregnant Jehovah's Witnesses 589 in secondary PPH 471 management of 46 maternal mortality 164 of sepsis 485 pathophysiology of 45 rare disorders 212–15 recognition of 418 in bleeding from lower genital tract 174 see also by pregife disorder coil deployment in non-targeted embolization 403 collagen-thrombin-fibrinogen patch 483 collateral arteries 400 community-based emergency care 542 FIGO guidelines on 612 competence (162 competence) 163 litigation over insufficient experience 532 surgeon experience 433 surgical management of placenta accreta 433 surgical competence (163 litigation over insufficient experience 532 surgeon experience 433 surgical management of placenta accreta 433 disporation ex exaction 435 competence 433 surgical management as 22 diabetes, and PPH risk 139 anteratal treatment of 194 dinoprost 358 diaporostone in first stage management accreta 453 diabetes, and PPH 157 deficient experience 532 diabetes, and PPH risk 139 anteratal treatment of 194 dinoprost 358 diaporostone in first stage management accreta 453 competence 433 surgical management as 22 diabetes, and PPH 157 deficient experience 532 litigation over insufficient experience 532 surgeon experience 433 surgical management as 23 competate 455 Competate 433 surgical management as 23 competate 453 competation as 24 diabetes, and PPH risk 139 anteratal treatment of 194 dinoprost 358 diaporostone in first stage management accreta 453 concalled 174 dinoprost 358 diabetes, and PPH risk 139 ante	· · · · · · · · · · · · · · · · · · ·		
circulating volume 73-9 assessment of 73 replenishment of 77 circulatory management 521 classifications, based on blood loss 129 based on causative factors 130 conventional temporal 129 of bleeding from lower genital tract 193 of PPH 82 pitfalls 130 proposed 131 volume deficit 130 coagulation at placental site 96 coagulation at placental site 96 coagulation asseade 481 coagulation asseade 481 coagulation system changes during pregnancy 199 coagulopathy 3, 78 acquired disorders of hemostasis 199-204 and PPH risk 140 consumptive 204-8 in obsterit hemorrhage 415 in placental abruption 229 in pregnant Jehovah's Witnesses 589 in secondary PPH 471 management of 46 maternal mortality 164 of sepsis 485 pathophysiology of 45 rare disorders 212-15 recognition of 418 in bleeding from lower genital tract 194 secondary PPH and 467 see also by specific disorder coil deployment in non-targeted cmbolization 403 collagen-thrombin-fibrinogen patch 483 collateral arteries 400 community-based emergency care 542 FIGO guidelines on 612 community-bacd emergency cas 542 EIGO guidelines on 612 community-bacd emergency cas 542 EIGO guidelines on 612 competence, lak of surgical competency 163 dehintions 133, 155, 550, 608 dehydration postabor 4 definitions 162 diabetes, and PPH risk 139 antenatal treatment of 194 disporation at placental discorders 38 diinoprostorie in first stage management and PPH 157 direct collectio			deen vein thrombosis after placenta
circulating volume 73-9 assessment of 73 replenishment of 77 replenishment of 78 replenishment of 77 replenishment of 77 replenishment of 129 replaced a Kefvartion over insufficient experience 433 surgical competency 163 litigation over insufficient experience dack of surgical competency 163 litigation over insufficient experience dack of surgical competency 163 litigation over insufficient experience dack of surgical competency 163 litigation over insufficient experience dactor 433 surgical management of placenta accreta 433 competenca dactor 433 replenta as surgical competency 163 litigation over insufficient experience dactor 433 replenta as surgical management of placenta accreta 433 replenta as surgical competence, 163 dabeysard anterable retains a deviation over insufficient experience data to 194 dinoprostone in first stage management and Child Health, changes in uterine competency afte			
assessment of 73 replenishment of 77 competence, competence, lack of surgical competency 163 litigation over insufficient experience based on blood loss 129 based on causative factors 130 conventional temporal 129 of bleeding from lower genital tract 193 of PPH 82 pitfalls 130 proposed 131 coagulation at placental site 96 coagulation cascade 481 coagulation as part of 'lethal triad' 24 consumptive 204-8 in placental abruption 229 in pregnant Jehovah's Witnesses 589 in secondary PPH at 71 management of 46 maternal mortality 164 of sepsis 485 pathophysiology of 45 rare disorders 212–15 recognition of 418 in bleeding from lower genital tract 194 secondary PPH and 467 see also by specific disorder coil deployment in non-targeted embolization 403 collagen-thrombim-fibrinogen patch 483 collateral arteries 400 competion and provided in the patch of serious distortion of 418 collateral arteries 400 competion and patch at 81 accollateral arteries 400 competion and prepared to some compension of 48 completion of 418 collateral arteries 400 controlled cord traction 115 collateral arteries 400 competion and prepared assistance on the patch of			
replenishment of 77 circulatory management 521 classifications, based on blood loss 129 based on causative factors 130 conventional temporal 129 of bleeding from lower genital tract 193 of PPH 82 pitiblis 130 proposed 131 volume deficit 130 coagulation at placental site 96 coagulation at placental site 96 coagulation system changes during pregnancy 199 coagulopathy 3, 78 acquired disorders of hemostasis 199-204 and PPH risk 140 as part of 'lethal triad' 24 consumptive 204-8 in placental abruption 229 in pregnang tybovah's Witneses 589 in secondary PPH 471 management of 46 maternal mortality 164 of sepsis 485 naternal treatment of 19			
classifications, based on blood loss 129 based on causative factors 130 conventional temporal 129 of bleeding from lower genital tract 193 of PPH 82 pitfalls 130 proposed 131 volume deficit 130 coagulation at placental site 96 coagulation system changes during pregnancy 199 coagulation system changes during pregnancy 199 coagulopathy 3, 78 acquired disorders of hemostasis 199–204 and PPH risk 140 as part of 'elethal triad' 24 consumptive 204–8 in obstetric hemorrhage 415 in placental abruption 229 in pregnant Jehovah's Witnesses 589 in secondary PPH 471 management of 46 maternal mortality 164 of spess 485 pathophysiology of 45 rare disorders 212—15 recognition of 418 in bleeding from lower genital tract 194 secondary PPH and 467 see also by specific disorder coil deployment in non-targeted embolization 403 collagen-thrombin-fibbrinogen patch 483 collateral arteries 400 lack of surgical competency 163 litigation over insufficient experience days auguen experience 433 surgical management of placenta accreta 453 compension sutures, compression suture accreta 453 compension usture, compression suture accreta 453 compension ustries, compression suture accreta 453 compension ustries, compression suture accreta 453 compension ustries, diaperal externet of 194 dimorption 259 dimorption 194 PPH 157 discheral extendent of placenta accreta 453 dimorption 194 direct collection of blood loss 83–6 disseminated intravascular coagulation 45, cfiliac artery ligation 457 Cho multiple square sutures 438 continuou terine compression suture 438, 453 coagulation at verine compression suture 438, 453 coagulation appearancy 199 concealed PPH 13 Confidential Enquiry into Maternal and Child Health, changes since 1985 162–7 recommendations 166 confounders when comparing international PPH statistics 134 congenital factor VII deficiency 415 congenital factor VII deficiency 415 congenital factor VII deficiency 415 consumptive coagulopathy 204		_	
classifications, based on blood loss 129 based on causative factors 130 conventional temporal 129 of bleeding from lower genital tract 193 of PPH 82 pitfalls 130 proposed 131 volume deficit 130 coagulation at placental site 96 coagulation system changes during pregnancy 199 coagulopathy 3, 78 acquired disorders of hemostasis 199-204 and PPH risk 140 as part of Tethal triad¹ 24 consumptive 204-8 in obstetric hemorrhage 415 in placental abruption 229 in pregnant Jehovah's Winesses 589 in secondary PPH 471 management of 46 maternal mortality 164 of sepsis 485 pathophysiology of 45 rare disorders 212-15 recognition of 418 in bleeding from lower genital tract to deployment in non-targeted embolization 403 collagen-thrombin-fibrinogen patch 483 collaterial atteries 400 ligation over insufficient experience 433 surgeon experience 453 surgeon experience 433 surgeon experience 453 surgeon 454 compression sutures compression sutures concaled PPH 147 Confidential Enquiry into Maternal and Cohild Health, changes since 1985 162-7 recommendations 166 confounders when comparing international PPH statistics 134 congenital disorders of hemostasis		*	
based on blood loss 129 based on causative factors 130 conventional temporal 129 of bleeding from lower genital tract 193 of PPH 82 pitfalls 130 proposed 131 volume deficit 130 coagulation at placental site 96 coagulation cascade 481 coagulation cascade 481 coagulation or system changes during pregnancy 199 coagulopathy 3, 78 acquired disorders of hemostasis 199-204 and PPH risk 140 as part of 'lethal triad' 24 consumptive 204-8 in obstetric hemorrhage 415 in placental abruption 229 in pregnant Jehovah's Witnesses 589 in secondary PPH 471 management of 46 maternal mortality 164 of sepsis 485 pathophysiology of 45 rare disorders 212-15 recognition of 418 in bleeding from lower genital tract 194 secondary PPH and 467 see also by specific disorder collagen-thrombin-fibrinogen patch 483 collagen-thrombin-fibrinogen patch 483 conventional temporal 129 surgeon experience 433 surgean experience 433 surgeal amanagement of placenta accreta 453 carcreta 453 charce stitch 452 Cho multiple square sutures 438 concaulation 457 Cho multiple square sutures 438 concaulation 457 Cho multiple square sutures 438 concaled PPH 13 Confidential Enquiry into Maternal and Child Health, changes since 1985 162-7 recommendations 166 confounders when comparing internations 166 confounders when comparing or patch 415 congenital disorders of hemostasis congenital disorders of hemostasis 140 conservative surgery 433-440 conservative surgery 435-440 conserv			
based on causative factors 130 conventional temporal 129 of bleeding from lower genital tract 193 of PPH 82 pitfalls 130 proposed 131 volume deficit 130 coagulation at placental site 96 coagulation at placental site 96 coagulation system changes during pregnancy 199 coagulopathy 3, 78 acquired disorders of hemostasis 199−204 and PPH risk 140 onsumptive 204−8 in placental abruption 229 in pregnant plebovah's Witnesses 589 in secondary PPH 471 management of 46 maternal mortality 164 of sepsis 485 pathophysiology of 45 rare disorders 212−15 recognition of 418 in bleeding from lower genital tract collagen-drombin-fibrinogen patch 483 collagen-drombin-fibrinogen patch 483 surgeon experience 433 surgical management of placenta afors placenta 453 compression sutures, compression sutures, compression sutures, cof ilika ettery ligation 457 collection of blood loss 83−6 dinoprostone in first stage management and PPH 157 direct collection of blood loss 83−6 dinoprostone in first stage management and PPH 157 direct collection of blood loss 83−6 direct collection of bl			
conventional temporal 129 of bleeding from lower genital tract 193 of PPH 82 pitfalls 130 proposed 131 coagulation at placental site 96 coagulation at placental site 96 coagulation cascade 481 coagulation system changes during pregnancy 199 coagulopathy 3, 78 acquired disorders of hemostasis in obstertic hemorrhage 415 in placental abruption 229 in pregnant Jehovah's Witnesses 589 in secondary PPH 471 management of 46 maternal mortality 164 of sepsis 485 pathophysiology of 45 rare disorders 212–15 recognition of 418 in bleeding from lower genital tract 194 secondary PPH and 467 see also by specific disorder collagen-thrombin-fibrinogen patch 483 collateral arteries 400 sompression sutures, and PPH 157 direct collection of blood loss 83–6 disseminated intravascular coagulation 45, 204–8 after endocervical tear 491 in abdominal pregnancy 583 in placental abruption 229, 230 documentation by midwife of PPH 551 Dominican Republic, misoprostol use in 286 Doppler analysis, esophageal 521 hemodynamic changes in uterine blood flow 89–93 imaging for placenta accreta 248, 249 intrapartum velocimetry 89 drills, cf skills and scenarios for training 307 drug-induced thrombocytopenia 202 duration of labor, PPH risk 141 secondary PPH 47 secondary PPH and 467 see also by specific disorder continuum of care model 555–60 controlations, inefficient and PPH 91 pathophysiology of PPH and 94–9 controlation of labor, PPH risk 141 congenital arteriovenous		surgeon experience 433	antenatal treatment of 194
of bleeding from lower genital tract 193 compression sutures, of PPH 82 B-Lynch 434-6, 438 pitfalls 130 brace stitch 452 proposed 131 cfiliac artery ligation 457 volume deficit 130 Cho multiple square sutures 438 coagulation at placental site 96 Hayman uterine compression suture coagulation cascade 481 438, 453 coagulation system changes during pregnancy 199 Confidential Enquiry into Maternal and Child Health, acquired disorders of hemostasis 199-204 consumptive 204-8 and PPH risk 140 confounders when comparing in placental abruption 229, 230 documentation by midwife of PPH 551 consumptive 204-8 consumptive 204-8 consumptive 204-8 in placental abruption 229 in pregnant Jehovah's Witnesses 589 in secondary PPH 471 congenital factor VII deficiency 415 of sepsis 485 are disorders and PPH risk 140 congenital factor VII deficiency 415 rare disorders 122-15 consumptive coagulopathy 204-8 rare disorders 122-15 consumptive coagulopathy 204-8 in bleeding from lower genital tract 194 secondary PPH and 467 see also by specific disorder conflowed embolization 403 collagen-thrombin-fibrinogen patch 483 collateral arteries 400 conventional temporal classification of 5 corposed 131 compression sutures 438 after endocervical tear 491 in abdominal pregnancy 583 in placental abruption 229, 230 documentation by midwife of PPH 551 Dominican Republic, misoprostol use in 286 Doppler analysis, esophageal 521 hemodynamic changes in uterine blood flow 89-93 imaging for placenta accreta 248, 249 intrapartum velocimetry 89 drills, cf skills and scenarios for training 307 drug-induced thrombocytopenia 202 duration of labor, PPH risk 141 dysfibrinogenemia 212, 213			
193 of PPH 82 pitfalls 130 proposed 131 volume deficit 130 coagulation at placental site 96 coagulation assacade 481 coagulation cascade 481 coagulation system changes during pregnancy 199 coagulopathy 3, 78 acquired disorders of hemostasis 199–204 and PPH risk 140 as part of 'lethal triad' 24 consumptive 204–8 in placental abruption 229 in pregnant Jehovah's Witnesses 589 in placental abruption 229 in pregnant Jehovah's Witnesses 589 in perganant Jehovah's Witnesses 589 pathophysiology of 45 rare disorders 212–15 recognition of 418 in bleeding from lower genital tract 194 sec also by specific disorder collagen-thrombin-fibrinogen patch 483 cogulation 452 direct collection of blood loss 83–6 disseminated intravascular coagulation 45, direct collection of blood loss 83–6 disseminated intravascular coagulation 45, after endocervical tear 491 in abdominal pregnancy 583 in placenta acreta 252 in placenta acreta 252 loboutinentations 166 confounders when comparing in abdominal pregnancy 583 in placenta acreta 252 loboutinentations 166 confounders when comparing in abdominal pregnancy 583 in placenta acre			
pitfalls 130 proposed 131 volume deficit 130 coagulation at placental site 96 coagulation at placental site 96 coagulation system changes during pregnancy 199 coagulopathy 3, 78 acquired disorders of hemostasis 199−204 and PPH risk 140 as part of 'lethal triad' 24 consumptive 204−8 in placental abruption 229 in pregnant Jehovah's Witnesses 589 in secondary PPH 471 management of 46 maternal mortality 164 of sepsis 485 pathophysiology of 45 rare disorders 212−15 recognition of 418 in bleeding from lower genital tract 194 secondary PPH and 467 see also by specific disorder coilagen−thrombin–fibrinogen patch 483 collagen−thrombin–fibrinogen patch 483 collagen−thrombin–fibrinogen patch 483 cogulated a traire vigation 457 Cho multiple square sutures 438 changes sure 1985 20 Hayman uterine compression suture 438, 453 concealed PPH 13 concealed PPH 13 Confidential Enquiry into Maternal and Child Health, Child Health, Child Health, Child Health, Changes since 1985 162−7 recommendations 166 confounders when comparing international PPH statistics 134 congenital arteriovenous malformations 128 confounders when comparing international PPH statistics 134 congenital disorders of hemostasis 218 congenital disorders of hemostasis 228 congenital factor VII deficiency 415 consumptive coagulopathy 204−8 continuum of care model 555−60 contructions, inefficient and PPH 91 pathophysiology of PPH and 94−9 controlled cord traction 115 active management without 116 embolization 403 collagen-thrombin–fibrinogen patch 483 collagen-thrombin–fibrinogen patch 483 collagen-thrombin–fibrinogen patch 483 collagen-thrombin–fibrinogen patch 483 collateral arteries 400 cordinates sutures 438 After endocervical tear 491 in abdominal pregnancy 583 in placenta abruption 229 in placenta abruption 229, 230 documentation by midwife of PPH 551 Dominican Republic, misoprostol use in 286 Doppler analysis, esophageal 521 hemodynamic changes in uterine blood flow 89–93 imaging for placenta abruption 229 diriting traction of labor. PPH risk 141 dysfibrinogen		compression sutures,	
volume deficit 130 Cho multiple square sutures 438 after endocervical tear 491 in abdominal pregnancy 583 in placenta accreta 252 in placental abruption 229, 230 documentation by midwife of PPH 551 Dominican Republic, misoprostol use in 286 apart of 'lethal triad' 24 consumptive 204—8 in secondary PPH 471 consumptive 204—8 in pregnant Jehovah's Witnesses 589 in secondary PPH 471 management of 46 maternal mortality 164 of sepsis 485 pathophysiology of 45 rare disorders 212–15 recognition of 418 in bleeding from lower genital tract 194 secondary PPH and 467 see also by specific disorder conburgeting and polarization 403 collagen—thrombin—fibrinogen patch 483 collateral arteries 400 consumption at the proof of the sure of the mortality 164 collateral arteries 400 conventional temporal classification of the sure of the molization for 412 conventional temporal classification of the sure of the molization of the sure of the molization for 412 conventional temporal classification of the sure of the modernia after endocervical tear 491 in abdominal pregnancy 583 in placental abcurvical safter endocervical tear 491 in abdominal pregnancy 583 in placental abcurvical safter endocervical tear 491 in abdominal pregnancy 583 in placental abcurvical safter endocervical tear 491 in abdominal pregnancy 583 in placental abcurvical safter endocervical tear 491 in abdominal pregnancy 583 in placental abcurvical accreta 252 in placental abcurvical accreta 252 in placental abcurvical occuration of pregnancy for PPH 515 100minican Republic, misoprostol use in 286 Doppler analysis, esophageal 521 hemodynamic changes in uterine blood flow 89–93 imaging for placenta accreta 248, 249 interpartum velocimetry 89 drills, of skills and scenarios for training 307 drug—induced thrombocytopenia 202 duration of labor, PPH incidence 157 PPH risk 141 dysfibrinogenemia 212, 213 carly varning score chart 18 early clamping of umbilical cord 105 early warning score chart 18 early varning score chart 18 econdary pyrexia after misoprostol in 204–8 corpo	of PPH 82	B-Lynch 434-6, 438	direct collection of blood loss 83-6
coagulation at placental site 96 coagulation cascade 481 coagulation system changes during pregnancy 199 coagulopathy 3, 78 acquired disorders of hemostasis 199−204 and PPH risk 140 as part of 'lethal triad' 24 consumptive 204−8 in obstetric hemorrhage 415 in placental abruption 229 in pregnant Jehovah's Witnesses 589 in secondary PPH 471 management of 46 maternal mortality 164 of sepsis 485 pathophysiology of 45 rare disorders 212−15 recognilop after 483 recognition of 418 in bleeding from lower genital tract 194 secondary PPH and 467 see also by specific disorder collagen—thrombin—fibrinogen patch 483 collagen—thrombin—fibrinogen patch 483 collagen—thrombin—fibrinogen patch 483 collagen—thrombin—fibrinogen patch 483 congenital atteriore on the management of 49 consumptive conventional temporal classification of collagen—thrombin—fibrinogen patch 483 conjequated with 483 conventional temporal classification of congenital atteries 400 Confounders when comparing confounders when comparing in threat trial	pitfalls 130	brace stitch 452	disseminated intravascular coagulation 45,
coagulation at placental site 96 coagulation cascade 481 coagulation system changes during pregnancy 199 coagulopathy 3, 78 acquired disorders of hemostasis 199-204 and PPH risk 140 as part of 'lethal triad' 24 consumptive 204-8 in obstetric hemorrhage 415 in placental abruption 229 in pregnant Jehovah's Witnesses 589 in secondary PPH 471 management of 46 maternal mortality 164 of sepsis 485 pathophysiology of 45 rare disorders 212-15 recognition of 418 in bleeding from lower genital tract 194 see also by specific disorder collagen-thrombin-fibrinogen patch 483 collagen-thrombin-fibrinogen patch 483 collagen-thrombin-fibrinogen patch 483 congulation excade 481 438, 453 in placental abruption 229, 230 documentation by midwife of PPH 551 Dominican Republic, misoprostol use in 286 Doppler analysis, esophageal 521 hemodynamic changes in uterine blood flow 89-93 imaging for placenta accreta 248, 249 intrapartum velocimetry 89 drills, of skills and scenarios for training 307 drug-induced thrombocytopenia 202 duration of labor, PPH incidence 157 PPH risk 141 dysfibrinogenemia 212, 213 contractions, inefficient and PPH 91 see also by specific disorder continuum of care model 555-60 contractions, inefficient and PPH and 94-9 see also by specific disorder continuum of cord traction 115 collagen-thrombin-fibrinogen patch 483 collagen-thrombin-fibrinogen patch 483 collagen-thrombin-fibrinogen patch 483 conventional temporal classification of	proposed 131	cf iliac artery ligation 457	204-8
coagulation cascade 481 coagulation system changes during pregnancy 199 coagulopathy 3, 78 acquired disorders of hemostasis 199−204 as part of 'lethal triad' 24 consumptive 204−8 in placental abruption 229, 230 confounders when comparing as part of 'lethal triad' 24 consumptive 204−8 in placental abruption 2415 in placental abruption 259 in pregnancy 199 confounders when comparing as part of 'lethal triad' 24 consumptive 204−8 in placental abruption 240 confounders when comparing as part of 'lethal triad' 24 consumptive 204−8 in placental abruption 259, 230 confounders when comparing in obstetric hemorrhage 415 in placental abruption 229, 286 Doppler analysis, esophageal 521 hemodynamic changes in uterine blood flow 89−93 imaging for placenta accreta 248, congenital disorders of hemostasis 249 in pregnant Jehovah's Witnesses 589 in secondary PPH 471 congenital factor VII deficiency 415 of sepsis 485 pathophysiology of 45 rare disorders 212−15 recognition of 418 in bleeding from lower genital tract 194 secondary PPH and 467 see also by specific disorder coil deployment in non-targeted embolization 403 collagen-thrombin-fibrinogen patch 483 collateral arteries 400 438, 453 in placental abruption 229, 230 documentation by midwife of PPH 551 Dominican Republic, misoprostol use in 286 Doppler analysis, esophageal 521 hemodynamic changes in uterine blood flow 89−93 imaging for placenta accreta 248, congenital disorders of hemostasis 249 intrapartum velocimetry 89 drills, cf skills and scenarios for training 307 drug-induced thrombocytopenia 202 duration of labor, PPH incidence 157 PPH risk 141 dysfibrinogenemia 212, 213 controlled cord traction 115 early clamping of umbilical cord 105 early clamping of umbilical cord 105 early warning score chart 18 ebb™ Complete Tamponade System FIGO guidelines on 609 technique 118 conventional temporal classification of 412 Ecuador, pyrexia after misoprostol in			
coagulation system changes during pregnancy 199 Confidential Enquiry into Maternal and Confidential Enquiry into Maternal and Child Health, changes since 1985 162–7 recommendations 166 and PPH risk 140 and PPH risk 140 consumptive 204–8 in becential abruption 229 in secondary PPH 471 congenital arteriovenous malformations in secondary PPH 471 management of 46 maternal mortality 164 of sepsis 485 pathophysiology of 45 rare disorders 212–15 recognition of 418 in bleeding from lower genital tract 194 secondary PPH and 467 see also by specific disorder secondage—and thrombin—fibrinogen patch 483 collateral arteries 400 consequiation system changes during pregnancy 199 (Confidential Enquiry into Maternal and Child Health, Changes since 1985 162–7 recommendations 166 confounders when comparing internations 166 confounders when comparing at treival 1985 162–7 recommendations 166 confounders when comparing internations 166 confounders when comparing a treatistics 134 congenital arteriovenous malformations 218 international PPH 91 simple for placenta accreta 248, 249 intrapartum velocimetry 89 drills, cf skills and scenarios for training 307 duration of labor, PPH incidence 157 recognition of 418 continuum of care model 555–60 consumptive coagulopathy 204–8 contractions, inefficient and PPH 91 pathophysiology of PPH and 94–9 controlled cord traction 115 early warning score chart 18 ebb™ Complete Tamponade System 369, 460 ectopic pregnancy, embolization for 412 conventional temporal classification of ectopic pregnancy, embolization for 412 ecuder, pyrexia after misoprostol in	coagulation at placental site 96	Hayman uterine compression suture	in abdominal pregnancy 583
coagulopathy 3, 78 acquired disorders of hemostasis 199-204			
coagulopathy 3, 78			
acquired disorders of hemostasis 199–204 recommendations 166 and PPH risk 140 as part of 'lethal triad' 24 congenital arteriovenous malformations in obstetric hemorrhage 415 in placental abruption 229 in pregnant Jehovah's Witnesses 589 in secondary PPH 471 management of 46 of sepsis 485 pathophysiology of 45 rare disorders 212–15 recognition of 418 in bleeding from lower genital tract 194 see also by specific disorder coil deployment in non-targeted embolization 403 collagen-thrombin-fibrinogen patch 483 collateral arteries 400 confounders when comparing recommendations 166 Doppler analysis, esophageal 521 hemodynamic changes in uterine blood flow 89–93 imaging for placenta accreta 248, 249 intrapartum velocimetry 89 drills, cf skills and scenarios for training 307 drug-induced thrombocytopenia 202 druation of labor, PPH incidence 157 PPH risk 141 dysfibrinogenemia 212, 213 early clamping of umbilical cord 105 early varning score chart 18 ebb TM Complete Tamponade System etchnique 118 econfounders when comparing international PPH statistics 134 hemodynamic changes in uterine hemodynamic changes in uterine blood flow 89–93 imaging for placenta accreta 248, 249 drills, cf skills and scenarios for training 307 drug-induced thrombocytopenia 202 druation of labor, PPH incidence 157 PPH risk 141 dysfibrinogenemia 212, 213 early clamping of umbilical cord 105 early varning score chart 18 ebb TM Complete Tamponade System 26b TM Complete Tamponade System 27b, 400 27collagen-thrombin-fibrinogen patch 483 conventional temporal classification of 28collagen-thrombin-fibrinogen patch 483 conventional temporal classification of			
199–204 recommendations 166 Doppler analysis, and PPH risk 140 confounders when comparing as part of 'lethal triad' 24 international PPH statistics 134 consumptive 204–8 congenital arteriovenous malformations in obstetric hemorrhage 415 in placental abruption 229 in pregnant Jehovah's Witnesses 589 in secondary PPH 471 congenital factor VII deficiency 415 management of 46 congenital platelet disorders 208 maternal mortality 164 connective tissue disorders and PPH risk of sepsis 485 pathophysiology of 45 rare disorders 212–15 recognition of 418 in bleeding from lower genital tract 194 secondary PPH and 467 see also by specific disorder coil deployment in non-targeted embolization 403 collagen-thrombin-fibrinogen patch 483 collateral arteries 400 recommendations 166 confounders when comparing international PPH statistics 134 confounders when comparing esophageal 521 hemodynamic changes in uterine blood flow 89–93 imaging for placenta accreta 248, drills, cf skills and scenarios for training 307 drug-induced thrombocytopenia 202 duration of labor, PPH incidence 157 PPH risk 141 dysfibrinogenemia 212, 213 contractions, inefficient and PPH 91 secondary PPH and 467 see also by specific disorder controlled cord traction 115 coil deployment in non-targeted embolization 403 collagen-thrombin-fibrinogen patch 483 collateral arteries 400 recommendation PPH statistics 134 hemodynamic changes in uterine blood flow 89–93 imaging for placenta accreta 248, drills, cf skills and scenarios for training drug-induced thrombocytopenia 202 duration of labor, PPH incidence 157 PPH risk 141 dysfibrinogenemia 212, 213 early clamping of umbilical cord 105 early clamping			
and PPH risk 140 as part of 'lethal triad' 24 consumptive 204–8 in obstetric hemorrhage 415 in placental abruption 229 in pregnant Jehovah's Witnesses 589 in secondary PPH 471 management of 46 maternal mortality 164 of sepsis 485 pathophysiology of 45 rare disorders 212–15 recognition of 418 in bleeding from lower genital tract 194 secondary PPH and 467 see also by specific disorder coil deployment in non-targeted embolization 403 collagen—thrombin—fibrinogen patch 483 collateral arteries 400 congenital arteriovenous malformations blood flow 89–93 imaging for placenta accreta 248, intrapartum velocimetry 89 drills, cf skills and scenarios for training duration of labor, conservative surgery 433–440 rossumptive coagulopathy 204–8 pPH incidence 157 PPH insk 141 qysfibrinogenemia 212, 213 contractions, inefficient and PPH 91 pathophysiology of PPH and 94–9 see also by specific disorder controlled cord traction 115 active management without 116 embolization 403 FIGO guidelines on 609 aforting the modynamic changes in uterine blood flow 89–93 imaging for placenta accreta 248, drills, cf skills and scenarios for training drug-induced thrombocytopenia 202 duration of labor, early clamping of umbilical cord 105 early clamping of umbilical cor			
as part of 'lethal triad' 24 international PPH statistics 134 consumptive 204–8 congenital arteriovenous malformations in obstetric hemorrhage 415 218 in placental abruption 229 congenital disorders of hemostasis in pregnant Jehovah's Witnesses 589 in secondary PPH 471 congenital factor VII deficiency 415 congenital platelet disorders 208 maternal mortality 164 connective tissue disorders and PPH risk of sepis 485 140 conservative surgery 433–440 rare disorders 212–15 consumptive coagulopathy 204–8 in bleeding from lower genital factor VII deficiency 415 continuum of care model 555–60 disorder 212–15 consumptive coagulopathy 204–8 in bleeding from lower genital factor VII deficiency 415 drills, cf skills and scenarios for training 307 drug-induced thrombocytopenia 202 duration of labor, PPH incidence 157 PPH risk 141 dysfibrinogenemia 212, 213 contractions, inefficient and PPH 91 secondary PPH and 467 see also by specific disorder contractions active management without 116 embolization 403 FIGO guidelines on 609 conventional temporal classification of 412 conventional temporal classification of 412 conventional temporal classification of			
consumptive 204–8 in obstetric hemorrhage 415 in placental abruption 229 in pregnant Jehovah's Witnesses 589 in secondary PPH 471 management of 46 maternal mortality 164 of sepsis 485 pathophysiology of 45 rare disorders 212–15 recognition of 418 in bleeding from lower genital tract 194 secondary PPH and 467 see also by specific disorder coil deployment in non-targeted embolization 403 collagen—thrombin–fibrinogen patch 483 conventional temporal classification of congenital arteriovenous malformations imaging for placenta accreta 248, intrapartum velocimetry 89 drills, cf skills and scenarios for training drills, cf skills and scenarios for training all officiency 415 drills, cf skills and scenarios for training drills, cf skills and scenarios for training all officiency 415 drills, cf skills and scenarios for training drills, cf skills and scenarios for training all officiency 415 drills, cf skills and scenarios for training all officiency 415 drills, cf skills and scenarios for training all officiency 415 drills, cf skills and scenarios for training all officiency 415 drills, cf skills and scenarios for training all officiency 415 drills, cf skills and scenarios for training all officiency 415 drills, cf skills and scenarios for training all officiency 415 drills, cf skills and scenarios for training all officiency 415 drills, cf skills and scenarios for training all officiency 415 drills, cf skills and scenarios for training all officiency 415 drills, cf skills and scenarios for training all officiency 415 drills, cf skills and scenarios for training all officiency 415 crayley art all officiency 415 drills, cf skills and scenarios for training all officiency 415 consumptive coagulopathy 204–8 pPH incidence 157 pPH risk 141 dysfibrinogenemia 212, 213 early clamping of umbilical cord 105 early clamping of umbi			
in obstetric hemorrhage 415 in placental abruption 229 in pregnant Jehovah's Witnesses 589 in secondary PPH 471 management of 46 maternal mortality 164 of sepsis 485 pathophysiology of 45 rare disorders 212−15 recognition of 418 in bleeding from lower genital tract 194 secondary PPH and 467 see also by specific disorder coil deployment in non-targeted embolization 403 collagen—thrombin—fibrinogen patch 483 collateral arteries 400 congenital disorders of hemostasis 249 intrapartum velocimetry 89 dirills, cf skills and scenarios for training odirills, cf skills and scenarios for training drills, cf s			
in placental abruption 229 in pregnant Jehovah's Witnesses 589 in secondary PPH 471 management of 46 maternal mortality 164 of sepsis 485 pathophysiology of 45 rare disorders 212–15 recognition of 418 in bleeding from lower genital tract 194 secondary PPH and 467 see also by specific disorder coil deployment in non-targeted embolization 403 collagen—thrombin—fibrinogen patch 483 collateral arteries 400 congenital disorders of hemostasis 249 intrapartum velocimetry 89 drills, cf skills and scenarios for training drug-induced thrombocytopenia 202 duration of labor, PPH incidence 157 PPH risk 141 dysfibrinogenemia 212, 213 contractions, inefficient and PPH 91 pathophysiology of PPH and 94–9 controlled cord traction 115 early warning score chart 18 ebb TM Complete Tamponade System FIGO guidelines on 609 369, 460 ectopic pregnancy, embolization for 412 conventional temporal classification of		e	
in pregnant Jehovah's Witnesses 589 in secondary PPH 471 congenital factor VII deficiency 415 congenital factor VII deficiency 415 drills, cf skills and scenarios for training 307 anagement of 46 congenital platelet disorders 208 and PPH risk of sepsis 485 and pathophysiology of 45 conservative surgery 433−440 and bleeding from lower genital tract 194 secondary PPH and 467 see also by specific disorder see also by specific disorder conbolization 403 acollagen−thrombin−fibrinogen patch 483 collateral arteries 400 see also 403 and 40			
in secondary PPH 471 congenital factor VII deficiency 415 drills, cf skills and scenarios for training management of 46 congenital platelet disorders 208 307 drug-induced thrombocytopenia 202 duration of labor, pathophysiology of 45 conservative surgery 433–440 pPH risk recognition of 418 continuum of care model 555–60 in bleeding from lower genital tract 194 secondary PPH and 467 see also by specific disorder see also by specific disorder controlled cord traction 115 see also by specific disorder some see also by specific disorder see also by s	*	e	
management of 46 maternal mortality 164 of sepsis 485 pathophysiology of 45 rare disorders 212–15 recognition of 418 in bleeding from lower genital tract 194 secondary PPH and 467 see also by specific disorder see also by specific disorder conlective tissue disorders and PPH risk duration of labor, PPH incidence 157 PPH risk 141 dysfibrinogenemia 212, 213 contractions, inefficient and PPH 91 pathophysiology of PPH and 94–9 see also by specific disorder controlled cord traction 115 coil deployment in non-targeted embolization 403 collagen—thrombin—fibrinogen patch 483 collateral arteries 400 conventional temporal classification of conventi			
maternal mortality 164 connective tissue disorders and PPH risk of sepsis 485 140 duration of labor, pathophysiology of 45 conservative surgery 433–440 PPH incidence 157 PPH incidence 157 rare disorders 212–15 consumptive coagulopathy 204–8 PPH risk 141 dysfibrinogenemia 212, 213 contractions, inefficient and PPH 91 secondary PPH and 467 pathophysiology of PPH and 94–9 see also by specific disorder controlled cord traction 115 early warning score chart 18 coil deployment in non-targeted embolization 403 FIGO guidelines on 609 technique 118 conventional temporal classification of Ecuador, pyrexia after misoprostol in			
of sepsis 485 pathophysiology of 45 conservative surgery 433–440 pathophysiology of 45 rare disorders 212–15 recognition of 418 in bleeding from lower genital tract 194 secondary PPH and 467 see also by specific disorder coil deployment in non-targeted embolization 403 collagen—thrombin—fibrinogen patch 483 conservative surgery 433–440 PPH incidence 157 PPH risk 141 dysfibrinogenemia 212, 213 contractions, inefficient and PPH 91 pathophysiology of PPH and 94–9 controlled cord traction 115 early warning score chart 18 ebb TM Complete Tamponade System gebpt active management without 116 embolization 403 FIGO guidelines on 609 collagen—thrombin—fibrinogen patch 483 conventional temporal classification of see also by specific disorder conventional temporal classification of see also by specific disorder conventional temporal classification of see also by specific disorder conventional temporal classification of see also by specific disorder conventional temporal classification of see also by specific disorder conventional temporal classification of see also by specific disorder conventional temporal classification of see also by specific disorder conventions conventional temporal classification of see also by specific disorder conventions conventions conventions see also by specific disorder conventions conv			
pathophysiology of 45 conservative surgery 433–440 PPH incidence 157 rare disorders 212–15 consumptive coagulopathy 204–8 PPH risk 141 recognition of 418 continuum of care model 555–60 dysfibrinogenemia 212, 213 in bleeding from lower genital contractions, inefficient and PPH 91 secondary PPH and 467 pathophysiology of PPH and 94–9 early clamping of umbilical cord 105 early warning score chart 18 coil deployment in non-targeted embolization 403 FIGO guidelines on 609 and 369, 460 ectopic pregnancy, embolization for 412 collateral arteries 400 conventional temporal classification of Ecuador, pyrexia after misoprostol in			
rare disorders 212–15 consumptive coagulopathy 204–8 PPH risk 141 recognition of 418 continuum of care model 555–60 dysfibrinogenemia 212, 213 in bleeding from lower genital in bleeding from lower genital contractions, inefficient and PPH 91 secondary PPH and 467 pathophysiology of PPH and 94–9 see also by specific disorder controlled cord traction 115 early warning score chart 18 coil deployment in non-targeted embolization 403 FIGO guidelines on 609 and 369, 460 collagen—thrombin—fibrinogen patch 483 conventional temporal classification of Ecuador, pyrexia after misoprostol in			
recognition of 418 continuum of care model 555–60 dysfibrinogenemia 212, 213 in bleeding from lower genital tract 194 inefficient and PPH 91 secondary PPH and 467 pathophysiology of PPH and 94–9 early clamping of umbilical cord 105 see also by specific disorder controlled cord traction 115 early warning score chart 18 coil deployment in non-targeted embolization 403 FIGO guidelines on 609 369, 460 collagen—thrombin—fibrinogen patch 483 conventional temporal classification of Ecuador, pyrexia after misoprostol in			
in bleeding from lower genital tract 194 contractions, inefficient and PPH 91 secondary PPH and 467 pathophysiology of PPH and 94–9 see also by specific disorder controlled cord traction 115 early warning score chart 18 coil deployment in non-targeted embolization 403 FIGO guidelines on 609 369, 460 collagen—thrombin—fibrinogen patch 483 technique 118 ectopic pregnancy, embolization for 412 collateral arteries 400 conventional temporal classification of Ecuador, pyrexia after misoprostol in			
tract 194 inefficient and PPH 91 secondary PPH and 467 pathophysiology of PPH and 94–9 see also by specific disorder controlled cord traction 115 early warning score chart 18 coil deployment in non-targeted embolization 403 FIGO guidelines on 609 369, 460 collagen—thrombin—fibrinogen patch 483 technique 118 ectopic pregnancy, embolization for 412 collateral arteries 400 conventional temporal classification of Ecuador, pyrexia after misoprostol in			-,
secondary PPH and 467 pathophysiology of PPH and 94–9 see also by specific disorder controlled cord traction 115 early warning score chart 18 coil deployment in non-targeted embolization 403 FIGO guidelines on 609 369, 460 collagen—thrombin—fibrinogen patch 483 technique 118 ectopic pregnancy, embolization for 412 collateral arteries 400 conventional temporal classification of Ecuador, pyrexia after misoprostol in		*	
see also by specific disordercontrolled cord traction 115early warning score chart 18coil deployment in non-targeted embolization 403active management without 116ebb™ Complete Tamponade Systemembolization 403FIGO guidelines on 609369, 460collagen-thrombin-fibrinogen patch 483technique 118ectopic pregnancy, embolization for 412collateral arteries 400conventional temporal classification ofEcuador, pyrexia after misoprostol in			early clamping of umbilical cord 105
coil deployment in non-targeted active management without 116 ebb™ Complete Tamponade System embolization 403 FIGO guidelines on 609 369, 460 ectopic pregnancy, embolization for 412 collateral arteries 400 conventional temporal classification of Ecuador, pyrexia after misoprostol in			
embolization 403 FIGO guidelines on 609 369, 460 collagen—thrombin—fibrinogen patch 483 technique 118 ectopic pregnancy, embolization for 412 collateral arteries 400 conventional temporal classification of Ecuador, pyrexia after misoprostol in			
collagen-thrombin-fibrinogen patch 483 technique 118 ectopic pregnancy, embolization for 412 collateral arteries 400 conventional temporal classification of Ecuador, pyrexia after misoprostol in			
collateral arteries 400 conventional temporal classification of Ecuador, pyrexia after misoprostol in			
	collateral uterine arteries 179		

education,	endometriosis and excessive bleeding at	external iliac artery, avoidance of
basic equipment list for practical	cesarean section and 449	accidental ligation 446
PPH training 309	endometritis 466, 469	extrinsic arteries of uterus 178
courses and workshops 518	endomyometritis 495	
drills teaching 307–8	England,	
for labor ward drills 305		C
	maternal morbidity 137	factor II, VII, IX and X (combined)
for visual estimation of blood loss 71	severe acute maternal morbidity in	deficiency 214
guide to PPH management poster	501	factor V deficiency 213
515	epidemiology comparing international	factor V Leiden as clue to history of PPH
hands-on training 516	PPH statistics 133–43	60
in development of hospital systems	epidural anesthesia and anticoagulant	factor V and VIII (combined) deficiency
for PPH 341		214
	therapy 207	
large volume transfusion protocol	epilepsy and PPH risk 140	factor VII,
349, 350	episiotomy,	recombinant activated 359, 415–28
learning from past mistakes 562-6	and PPH risk 143	clinical effect 418
lecture-based training 516	as cause of hemorrhage 194	mechanism of action 417
low fidelity models 517	for vaginal trauma treatment 4	pharmacokinetic studies of 417
MamaNatalie® birthing simulator	equipment,	production of 416
602–3	1 1	recommendations for use in
	basic list for practical PPH training	
maternal mortality reduction and	309	PPH 427-8
education of women in low	preparedness for PPH 314-15	safety 419, 427
resource settings 543	tray for PPH 314	worldwide experience with
modern teaching/learning modalities	ergometrine,	420-6
514–18	contraindications 114	recombinant vs. plasma-derived 417
Obstetric Hemorrhage Education	for uterine atony 357	structure of human 416
Project 348–50	isolation of 355	factor VII deficiency 213
practical emergency training 312	plus oxytocin vs. oxytocin alone	factor VIII deficiency,
preparation for PPH management	103	and PPH 96
305–10	side-effects 357	and secondary PPH 467
scenario teaching 309–10	storage costs 115	factor VIII inhibitors 206
self-learning of uterine vascular	use in secondary PPH 469	factor X deficiency 214
supply 23	warning on use 66	factor XI deficiency 214
simulations 516	ergot, as historical therapy 355	factor XIII deficiency 214
skills stations 349	ergot alkaloids,	FAST HUG approach 525
skills teaching 308–9	FIGO guidelines on use 612	febrile non-hemolytic transfusion reaction
techniques for 305–6	prophylactic use of 104	39
training and reduction of severe	vs. oxytocin 102	fertility,
		after embolization 411
acute maternal morbidity	ergotoxine 355	
510	esophageal Doppler 521	after internal iliac artery ligation 457
training for teamwork 562–6	ethanolamine oleate use with gelatin	after placenta accreta 260
training of midwives 552	sponge 404	maintenance of with internal iliac
Egypt, non-pneumatic anti-shock	ethics,	artery ligation 445
garment trials in 322–7	cell salvage methods in Jehovah's	fetal anomalies and risk of placenta previa
embolization,	Witnesses 579	231
· · · · · · · · · · · · · · · · · · ·		
and balloon catheter placement	considerations in hospital-based near	fetal nutrient requirements and PPH 59
398–412	miss research 151	fetomaternal hemorrhage 191
bilateral of uterine artery 470	of misoprostol use 287	fetomaternal transfusion and early
complications 398, 409	use of fibrin sealants in Jehovah's	clamping 105
contraindications 398	Witnesses 475	fibrin sealants 474–6, 480–5
for ectopic pregnancy 412	ethnicity,	
		method of use illustrations 478-9
	•	method of use illustrations 478–9
for vascular malformations 220	PPH incidence 156	patch 482
imaging for 406	PPH incidence 156 PPH risk 139	patch 482 spray 482
	PPH incidence 156	patch 482 spray 482 fibrinogen,
imaging for 406	PPH incidence 156 PPH risk 139	patch 482 spray 482
imaging for 406 importance of arterial knowledge in radiographers 6	PPH incidence 156 PPH risk 139 etiology,	patch 482 spray 482 fibrinogen, cf cryoprecipitate 46
imaging for 406 importance of arterial knowledge in radiographers 6 in placenta accreta 408	PPH incidence 156 PPH risk 139 etiology, of acute uterine inversion 185 of PPH 65, 138–9	patch 482 spray 482 fibrinogen, cf cryoprecipitate 46 cf fresh frozen plasma and
imaging for 406 importance of arterial knowledge in radiographers 6 in placenta accreta 408 location for and arterial puncture	PPH incidence 156 PPH risk 139 etiology, of acute uterine inversion 185 of PPH 65, 138–9 EUPHRATES study 109–12	patch 482 spray 482 fibrinogen, cf cryoprecipitate 46 cf fresh frozen plasma and cryoprecipitate 50
imaging for 406 importance of arterial knowledge in radiographers 6 in placenta accreta 408 location for and arterial puncture 406	PPH incidence 156 PPH risk 139 etiology, of acute uterine inversion 185 of PPH 65, 138–9 EUPHRATES study 109–12 Europe,	patch 482 spray 482 fibrinogen, cf cryoprecipitate 46 cf fresh frozen plasma and cryoprecipitate 50 early use in PPH 45–7
imaging for 406 importance of arterial knowledge in radiographers 6 in placenta accreta 408 location for and arterial puncture 406 logistics of 411	PPH incidence 156 PPH risk 139 etiology, of acute uterine inversion 185 of PPH 65, 138–9 EUPHRATES study 109–12 Europe, B-Lynch suture compression suture	patch 482 spray 482 fibrinogen, cf cryoprecipitate 46 cf fresh frozen plasma and cryoprecipitate 50 early use in PPH 45–7 fibrinogen replacement therapy 49
imaging for 406 importance of arterial knowledge in radiographers 6 in placenta accreta 408 location for and arterial puncture 406 logistics of 411 materials for 400–5	PPH incidence 156 PPH risk 139 etiology, of acute uterine inversion 185 of PPH 65, 138–9 EUPHRATES study 109–12 Europe, B-Lynch suture compression suture use in 438	patch 482 spray 482 fibrinogen, cf cryoprecipitate 46 cf fresh frozen plasma and cryoprecipitate 50 early use in PPH 45–7 fibrinogen replacement therapy 49 inherited abnormalities of 212
imaging for 406 importance of arterial knowledge in radiographers 6 in placenta accreta 408 location for and arterial puncture 406 logistics of 411	PPH incidence 156 PPH risk 139 etiology, of acute uterine inversion 185 of PPH 65, 138–9 EUPHRATES study 109–12 Europe, B-Lynch suture compression suture	patch 482 spray 482 fibrinogen, cf cryoprecipitate 46 cf fresh frozen plasma and cryoprecipitate 50 early use in PPH 45–7 fibrinogen replacement therapy 49
imaging for 406 importance of arterial knowledge in radiographers 6 in placenta accreta 408 location for and arterial puncture 406 logistics of 411 materials for 400–5	PPH incidence 156 PPH risk 139 etiology, of acute uterine inversion 185 of PPH 65, 138–9 EUPHRATES study 109–12 Europe, B-Lynch suture compression suture use in 438	patch 482 spray 482 fibrinogen, cf cryoprecipitate 46 cf fresh frozen plasma and cryoprecipitate 50 early use in PPH 45–7 fibrinogen replacement therapy 49 inherited abnormalities of 212
imaging for 406 importance of arterial knowledge in radiographers 6 in placenta accreta 408 location for and arterial puncture 406 logistics of 411 materials for 400–5 methods of action of embolic materials 402	PPH incidence 156 PPH risk 139 etiology, of acute uterine inversion 185 of PPH 65, 138–9 EUPHRATES study 109–12 Europe, B-Lynch suture compression suture use in 438 severe acute maternal morbidity in 501	patch 482 spray 482 fibrinogen, cf cryoprecipitate 46 cf fresh frozen plasma and cryoprecipitate 50 early use in PPH 45–7 fibrinogen replacement therapy 49 inherited abnormalities of 212 role in massive transfusion 35 use in PPH 48
imaging for 406 importance of arterial knowledge in radiographers 6 in placenta accreta 408 location for and arterial puncture 406 logistics of 411 materials for 400–5 methods of action of embolic materials 402 non-target 6	PPH incidence 156 PPH risk 139 etiology, of acute uterine inversion 185 of PPH 65, 138–9 EUPHRATES study 109–12 Europe, B-Lynch suture compression suture use in 438 severe acute maternal morbidity in 501 European consensus on prevention and	patch 482 spray 482 fibrinogen, cf cryoprecipitate 46 cf fresh frozen plasma and cryoprecipitate 50 early use in PPH 45–7 fibrinogen replacement therapy 49 inherited abnormalities of 212 role in massive transfusion 35 use in PPH 48 fibroids,
imaging for 406 importance of arterial knowledge in radiographers 6 in placenta accreta 408 location for and arterial puncture 406 logistics of 411 materials for 400–5 methods of action of embolic materials 402 non-target 6 of pelvic artery in placenta accreta	PPH incidence 156 PPH risk 139 etiology, of acute uterine inversion 185 of PPH 65, 138–9 EUPHRATES study 109–12 Europe, B-Lynch suture compression suture use in 438 severe acute maternal morbidity in 501 European consensus on prevention and management of PPH 109–12	patch 482 spray 482 fibrinogen, cf cryoprecipitate 46 cf fresh frozen plasma and cryoprecipitate 50 early use in PPH 45–7 fibrinogen replacement therapy 49 inherited abnormalities of 212 role in massive transfusion 35 use in PPH 48 fibroids, and PPH risk 140
imaging for 406 importance of arterial knowledge in radiographers 6 in placenta accreta 408 location for and arterial puncture 406 logistics of 411 materials for 400–5 methods of action of embolic materials 402 non-target 6 of pelvic artery in placenta accreta 253	PPH incidence 156 PPH risk 139 etiology, of acute uterine inversion 185 of PPH 65, 138–9 EUPHRATES study 109–12 Europe, B-Lynch suture compression suture use in 438 severe acute maternal morbidity in 501 European consensus on prevention and management of PPH 109–12 evolution and PPH 55–61	patch 482 spray 482 fibrinogen, cf cryoprecipitate 46 cf fresh frozen plasma and cryoprecipitate 50 early use in PPH 45–7 fibrinogen replacement therapy 49 inherited abnormalities of 212 role in massive transfusion 35 use in PPH 48 fibroids, and PPH risk 140 secondary PPH after 466
imaging for 406 importance of arterial knowledge in radiographers 6 in placenta accreta 408 location for and arterial puncture 406 logistics of 411 materials for 400–5 methods of action of embolic materials 402 non-target 6 of pelvic artery in placenta accreta 253 of uterine artery 405	PPH incidence 156 PPH risk 139 etiology, of acute uterine inversion 185 of PPH 65, 138–9 EUPHRATES study 109–12 Europe, B-Lynch suture compression suture use in 438 severe acute maternal morbidity in 501 European consensus on prevention and management of PPH 109–12 evolution and PPH 55–61 expectant management,	patch 482 spray 482 fibrinogen, cf cryoprecipitate 46 cf fresh frozen plasma and cryoprecipitate 50 early use in PPH 45–7 fibrinogen replacement therapy 49 inherited abnormalities of 212 role in massive transfusion 35 use in PPH 48 fibroids, and PPH risk 140 secondary PPH after 466 fibrosis of vesicouterine plane 265
imaging for 406 importance of arterial knowledge in radiographers 6 in placenta accreta 408 location for and arterial puncture 406 logistics of 411 materials for 400–5 methods of action of embolic materials 402 non-target 6 of pelvic artery in placenta accreta 253	PPH incidence 156 PPH risk 139 etiology, of acute uterine inversion 185 of PPH 65, 138–9 EUPHRATES study 109–12 Europe, B-Lynch suture compression suture use in 438 severe acute maternal morbidity in 501 European consensus on prevention and management of PPH 109–12 evolution and PPH 55–61 expectant management, cf active 105	patch 482 spray 482 fibrinogen, cf cryoprecipitate 46 cf fresh frozen plasma and cryoprecipitate 50 early use in PPH 45–7 fibrinogen replacement therapy 49 inherited abnormalities of 212 role in massive transfusion 35 use in PPH 48 fibroids, and PPH risk 140 secondary PPH after 466
imaging for 406 importance of arterial knowledge in radiographers 6 in placenta accreta 408 location for and arterial puncture 406 logistics of 411 materials for 400–5 methods of action of embolic materials 402 non-target 6 of pelvic artery in placenta accreta 253 of uterine artery 405	PPH incidence 156 PPH risk 139 etiology, of acute uterine inversion 185 of PPH 65, 138–9 EUPHRATES study 109–12 Europe, B-Lynch suture compression suture use in 438 severe acute maternal morbidity in 501 European consensus on prevention and management of PPH 109–12 evolution and PPH 55–61 expectant management,	patch 482 spray 482 fibrinogen, cf cryoprecipitate 46 cf fresh frozen plasma and cryoprecipitate 50 early use in PPH 45–7 fibrinogen replacement therapy 49 inherited abnormalities of 212 role in massive transfusion 35 use in PPH 48 fibroids, and PPH risk 140 secondary PPH after 466 fibrosis of vesicouterine plane 265 FIGO,
imaging for 406 importance of arterial knowledge in radiographers 6 in placenta accreta 408 location for and arterial puncture 406 logistics of 411 materials for 400–5 methods of action of embolic materials 402 non-target 6 of pelvic artery in placenta accreta 253 of uterine artery 405 preparation before 405 pressure needed for 405	PPH incidence 156 PPH risk 139 etiology, of acute uterine inversion 185 of PPH 65, 138–9 EUPHRATES study 109–12 Europe, B-Lynch suture compression suture use in 438 severe acute maternal morbidity in 501 European consensus on prevention and management of PPH 109–12 evolution and PPH 55–61 expectant management, cf active 105 cf AMTSL 126	patch 482 spray 482 fibrinogen, cf cryoprecipitate 46 cf fresh frozen plasma and cryoprecipitate 50 early use in PPH 45–7 fibrinogen replacement therapy 49 inherited abnormalities of 212 role in massive transfusion 35 use in PPH 48 fibroids, and PPH risk 140 secondary PPH after 466 fibrosis of vesicouterine plane 265 FIGO, FIGO 2012 PPH guideline for low
imaging for 406 importance of arterial knowledge in radiographers 6 in placenta accreta 408 location for and arterial puncture 406 logistics of 411 materials for 400–5 methods of action of embolic materials 402 non-target 6 of pelvic artery in placenta accreta 253 of uterine artery 405 preparation before 405 pressure needed for 405 targets of 406	PPH incidence 156 PPH risk 139 etiology, of acute uterine inversion 185 of PPH 65, 138–9 EUPHRATES study 109–12 Europe, B-Lynch suture compression suture use in 438 severe acute maternal morbidity in 501 European consensus on prevention and management of PPH 109–12 evolution and PPH 55–61 expectant management, cf active 105 cf AMTSL 126 exsanguinating patient as a model for	patch 482 spray 482 fibrinogen, cf cryoprecipitate 46 cf fresh frozen plasma and cryoprecipitate 50 early use in PPH 45–7 fibrinogen replacement therapy 49 inherited abnormalities of 212 role in massive transfusion 35 use in PPH 48 fibroids, and PPH risk 140 secondary PPH after 466 fibrosis of vesicouterine plane 265 FIGO, FIGO 2012 PPH guideline for low resource countries 67
imaging for 406 importance of arterial knowledge in radiographers 6 in placenta accreta 408 location for and arterial puncture 406 logistics of 411 materials for 400–5 methods of action of embolic materials 402 non-target 6 of pelvic artery in placenta accreta 253 of uterine artery 405 preparation before 405 pressure needed for 405 targets of 406 emergency care in low resource settings	PPH incidence 156 PPH risk 139 etiology, of acute uterine inversion 185 of PPH 65, 138–9 EUPHRATES study 109–12 Europe, B-Lynch suture compression suture use in 438 severe acute maternal morbidity in 501 European consensus on prevention and management of PPH 109–12 evolution and PPH 55–61 expectant management, cf active 105 cf AMTSL 126 exsanguinating patient as a model for PPH management 24–7	patch 482 spray 482 fibrinogen, cf cryoprecipitate 46 cf fresh frozen plasma and cryoprecipitate 50 early use in PPH 45–7 fibrinogen replacement therapy 49 inherited abnormalities of 212 role in massive transfusion 35 use in PPH 48 fibroids, and PPH risk 140 secondary PPH after 466 fibrosis of vesicouterine plane 265 FIGO, FIGO 2012 PPH guideline for low resource countries 67 guidelines for PPH prevention and
imaging for 406 importance of arterial knowledge in radiographers 6 in placenta accreta 408 location for and arterial puncture 406 logistics of 411 materials for 400–5 methods of action of embolic materials 402 non-target 6 of pelvic artery in placenta accreta 253 of uterine artery 405 preparation before 405 pressure needed for 405 targets of 406 emergency care in low resource settings 543, 559	PPH incidence 156 PPH risk 139 etiology, of acute uterine inversion 185 of PPH 65, 138–9 EUPHRATES study 109–12 Europe, B-Lynch suture compression suture use in 438 severe acute maternal morbidity in 501 European consensus on prevention and management of PPH 109–12 evolution and PPH 55–61 expectant management, cf active 105 cf AMTSL 126 exsanguinating patient as a model for PPH management 24–7 external abdominal pressure,	patch 482 spray 482 fibrinogen, cf cryoprecipitate 46 cf fresh frozen plasma and cryoprecipitate 50 early use in PPH 45–7 fibrinogen replacement therapy 49 inherited abnormalities of 212 role in massive transfusion 35 use in PPH 48 fibroids, and PPH risk 140 secondary PPH after 466 fibrosis of vesicouterine plane 265 FIGO, FIGO 2012 PPH guideline for low resource countries 67 guidelines for PPH prevention and treatment in 607–18
imaging for 406 importance of arterial knowledge in radiographers 6 in placenta accreta 408 location for and arterial puncture 406 logistics of 411 materials for 400–5 methods of action of embolic materials 402 non-target 6 of pelvic artery in placenta accreta 253 of uterine artery 405 preparation before 405 pressure needed for 405 targets of 406 emergency care in low resource settings 543, 559 Empress Mumtaz 64	PPH incidence 156 PPH risk 139 etiology, of acute uterine inversion 185 of PPH 65, 138–9 EUPHRATES study 109–12 Europe, B-Lynch suture compression suture use in 438 severe acute maternal morbidity in 501 European consensus on prevention and management of PPH 109–12 evolution and PPH 55–61 expectant management, cf active 105 cf AMTSL 126 exsanguinating patient as a model for PPH management 24–7 external abdominal pressure, anti-shock 336	patch 482 spray 482 fibrinogen, cf cryoprecipitate 46 cf fresh frozen plasma and cryoprecipitate 50 early use in PPH 45–7 fibrinogen replacement therapy 49 inherited abnormalities of 212 role in massive transfusion 35 use in PPH 48 fibroids, and PPH risk 140 secondary PPH after 466 fibrosis of vesicouterine plane 265 FIGO, FIGO 2012 PPH guideline for low resource countries 67 guidelines for PPH prevention and treatment in 607–18 joint statement with ICM on
imaging for 406 importance of arterial knowledge in radiographers 6 in placenta accreta 408 location for and arterial puncture 406 logistics of 411 materials for 400–5 methods of action of embolic materials 402 non-target 6 of pelvic artery in placenta accreta 253 of uterine artery 405 preparation before 405 pressure needed for 405 targets of 406 emergency care in low resource settings 543, 559	PPH incidence 156 PPH risk 139 etiology, of acute uterine inversion 185 of PPH 65, 138–9 EUPHRATES study 109–12 Europe, B-Lynch suture compression suture use in 438 severe acute maternal morbidity in 501 European consensus on prevention and management of PPH 109–12 evolution and PPH 55–61 expectant management, cf active 105 cf AMTSL 126 exsanguinating patient as a model for PPH management 24–7 external abdominal pressure,	patch 482 spray 482 fibrinogen, cf cryoprecipitate 46 cf fresh frozen plasma and cryoprecipitate 50 early use in PPH 45–7 fibrinogen replacement therapy 49 inherited abnormalities of 212 role in massive transfusion 35 use in PPH 48 fibroids, and PPH risk 140 secondary PPH after 466 fibrosis of vesicouterine plane 265 FIGO, FIGO 2012 PPH guideline for low resource countries 67 guidelines for PPH prevention and treatment in 607–18

modern teaching/learning modalities for PPH management 514	rectus sheath 14	obstetric hemorrhage equipment tray in 314
recommendations 118	retroperitoneal 14 secondary PPH after 466	out-of-hospital deliveries 571–4
for non-pneumatic anti-shock	vaginal, topical hemostatic agents for	preparation of, labor ward drills
garment 318	485	305–10
Finland,	hemodynamics,	preparation protocols for
severe acute maternal morbidity in	changes in uterine blood flow	management of PPH 343
506	89–93	proposed management scheme
unplanned home deliveries in 572	changes in uterus during pregnancy	within 343
FloSeal 480–5	177–83	systems for care of women with
Foley catheter 379	during pregnancy 180–3	PPH 341–7
fondaparinux use during pregnancy 207	of pneumatic anti-shock garment use	Huntington technique for acute uterine
forceps delivery and PPH 6	334	inversion 187 hydrostatic condom catheter 379
France, accurate PPH rate determination	prepregnancy 177–81 hemoglobin,	hydrostatic intrauterine balloon
153	determination of changes in 84	tamponade, FIGO guidelines
maternal mortality 136	restoration of levels 78	on 615
severe acute maternal morbidity in	hemolytic disease of the newborn 31	hyperkalemia 27
501	hemolytic uremic syndrome 203	hypertension 82
use of anti-shock garments in 320	hemophilia 211–12	malignant 533
fresh frozen plasma 32	in secondary PPH 471	see also pre-eclampsia
fundus,	recombinant activated factor VII for	hypocalcemia 27, 40
fetal delivery through 11	415	hypofibrinogenemia 35, 212, 213
postpartum pathology of 493–4	secondary PPH and 467	hypogastric artery, see internal iliac artery
	hemorrhagic shock,	hypokalemia 27, 40
Cit 210	cardiovascular physiology of 332	hypotension and leukocyte depletion
G-suit 319	choice of volume expansion fluid for 77	filters 581 hypothermia 40
gelatin sponge 400, 470 gelatin–thrombin matrix 480, 482, 483	decreased recovery times with	as part of 'lethal triad' 24
gemeprost 358	non-pneumatic anti-shock	hypovolemia-related complications 409
Glanzmann's thrombasthenia 208, 415	garment 323	hypovolemic shock 73
Glasgow Coma Scale 523	early recognition of 24	as a cause of consumptive
glues,	identification of 550	coagulopathy 205
effect on vascular system 403	in acute uterine inversion 185	cardiovascular physiology of 332
fibrin sealants 474–6, 480–5	in placental abruption 230	choice of volume expansion fluid for
method of use illustrations for fibrin	internal iliac artery ligation for 444	77
sealants 478–9	stages of 74	decreased recovery times with
topical hemostatic agents 480–5	hemostasis,	non-pneumatic anti-shock
gravimetric method of blood loss measurement 84	after placenta accreta surgery 269 congenital disorders of 208–10	garment 323 early recognition of 24
guide to PPH management poster 515	disorders of 199–215	identification of 550
guidelines,	mechanism of by factor VII 417–18	in acute uterine inversion 185
current guidance for clinicians on	use in Jehovah's Witnesses 590	in placental abruption 230
ALTSL 124	hemostatic dressings 25	internal iliac artery ligation for 444
FIGO 2012 PPH guideline for low	hemostatic resuscitation 25	stages of 74
resource countries 67	heparin use during pregnancy 206	hysterectomy 453
for PPH prevention and treatment in	heparin-induced thrombocytopenia 202	adherent placenta and 11
607–18	hepatitis C and litigation 530	after uterine rupture 189
for uterine-specific balloons 392	history,	as treatment for S1 and S2 bleeding
Guinea, severe acute maternal morbidity	maternal mortality 545	(1
in 501	of anti-shock garments 331 of PPH 545	avoidance of by having obstetric
	previous cesarean and PPH risk	hemorrhage equipment tray 315
Haultian technique for acute uterine	141	cf balloon tamponade 383
inversion 187	previous PPH and PPH risk 141,	comparisons 509
Hayman uterine compression suture 438,	156	consent for in management of
453	therapies used for PPH 355	placenta accreta 253
health care infrastructure in India 542-4	HIV,	for supralevator hematoma 197
heart valve prostheses 207	cell salvage methods contraindicated	impact of new hospital systems on
HELLP syndrome 40, 82	by 578	incidence 345
cell salvage methods in 579	HIV-associated thrombocytopenia	incidence of emergency 458
severe acute maternal morbidity in	202	pathology of uterine specimens from
504	litigation 529 home deliveries 571–4	489–97
with pre-eclampsia 203 hematocrit,		peripartum 462–4
		impact of next hospital systems
CHANGES III AND FEET CLASSIFICATION	home-based life-saving skills, FIGO	impact of new hospital systems on incidence 346
changes in and PPH classification 129	home-based life-saving skills, FIGO guidelines on use 612	on incidence 346
	home-based life-saving skills, FIGO guidelines on use 612 hospitals,	on incidence 346 indications for 462
129	home-based life-saving skills, FIGO guidelines on use 612	on incidence 346
129 PPH definition from 155	home-based life-saving skills, FIGO guidelines on use 612 hospitals, hospital-based near miss research	on incidence 346 indications for 462 severe acute maternal morbidity
129 PPH definition from 155 hematoma, estimation of size by imaging 406 management of 196–8	home-based life-saving skills, FIGO guidelines on use 612 hospitals, hospital-based near miss research 150 impact of new systems on outcome 344	on incidence 346 indications for 462 severe acute maternal morbidity after 507 surgical principles of 463–4 use in Japan 171
129 PPH definition from 155 hematoma, estimation of size by imaging 406	home-based life-saving skills, FIGO guidelines on use 612 hospitals, hospital-based near miss research 150 impact of new systems on outcome	on incidence 346 indications for 462 severe acute maternal morbidity after 507 surgical principles of 463–4

idiopathic thrombocytopenic purpura	International Collaborative Group 154	labor duration and PPH risk 141
200	International Confederation of Midwives	labor induction,
Illinois model of training 348–50	(ICM),	after fetal death 278
incidental thrombocytopenia 200	joint statement with FIGO on	and PPH risk 141
India,	Management of Third Stage	by misoprostol 278, 285
abdominal pregnancy hemorrhage	of Labor to Prevent PPH	labor ward drills 305–10
experience 583–6	121	assessment of visual blood loss
health care infrastructure 542–4	modern teaching/learning modalities	estimation 71
MamaNatalie® newborn simulator	for PPH management 514	lacunae, placental 248
trials 603	recommendations 118	large volume transfusion protocol 349,
management of PPH in 539	for non-pneumatic anti-shock	350
surgical management of placenta	garment 318	Latin America, severe acute maternal
accreta in 454	intimate partner abuse and abdominal	morbidity in 501
Indonesia, severe acute maternal	trauma 189–91	learning processes 305
morbidity in 501	intra-abdominal pressure and	leiomyomata,
induction of labor,	non-pneumatic anti-shock	postpartum pathology of 495
by misoprostol 285	garment use 338	uterine atony risk and 356
PPH incidence 156		'lethal triad' 24
	intraluminal pressure,	
PPH risk 141	pressure readings 369–75	leukocyte depletion filters 580
infection,	corresponding blood pressures	levator ani muscle, sutured injury of 14
after embolization 410	373	ligation,
after placenta accreta 260	of different balloons 370	accidental 446
peripartum hysterectomy and sepsis	relationship with systolic blood	of internal iliac artery 441-7, 455-7
463	pressure 374	of uterine artery 452
septic transfusion reaction 37	intraoperative aortic compression 10	ligature placement for stepwise
infralevator hematoma 196	intraoperative autologous blood	devascularization 439
	transfusions 577–82	
inherited abnormalities of fibrinogen		litigation 527–35
212–15	intraoperative cell salvage 592	abandonment 535
inotropes 522	use in Jehovah's Witnesses 590	dangerous sidewalk 527
instrumental delivery,	intrapartum PPH prevention 550	delay in transfusion 530
failed 9	intraperitoneal hemorrhage 164	disappearing baby 534
genital tract trauma and maternal	intraplacental lacunae 241	early discharge 531
mortality 164	intrauterine fetal death, misoprostol use	first maternal death litigation 527
PPH incidence and 156	after 286	health insurance 528
PPH scenario 5	intrinsic arteries of uterus 179	hepatitis C 530
		HIV 529
intensive care management 520–5	invasive pattern of human placentation	
airway 520		iatrogenic obstetric injury 528
breathing 520	inverted uterus,	inadequate staffing 532
circulatory 521	hydrostatic repositioning 16	infections after transfusion 529
discharge and follow-up 525	manual repositioning 15	insufficient experience 532
FAST HUG approach 525	Ireland, severe acute maternal morbidity	malignant hypertension 533
gastrointestinal 524	in 507	no autopsy 532
general management 524	iron overload 27	no expert medical report 533
hematological 524	ischemia, postembolic 410	no operation note 533
neurological 523	ischemic necrosis of distal organs, in	obstetrician on vacation 531
pain relief and sedation 524		PPH in an aircraft 534
-	placental abruption 230	
renal 523	isoimmunization in placental abruption	PPH in dog 535
sepsis 524	230	PPH into pleural cavity 534
internal iliac artery,	isthmial tourniquet 451	road traffic accident 528
anastomoses of 442	Italy, experience with internal uterine	Sheehan syndrome 533
anatomy of 441	tamponade 381–5	suing wrong doctor 532
bilateral vs. unilateral ligation 443		telephone problem 528
ligation of 441–7, 455–7		transfusion of wrong blood 528
accidental ligation of common	Japan, declining maternal mortality rate in	unlawful practice of medicine 527
or external iliac artery 446	169–74	unlicensed practice of obstetrics 531
anatomic considerations 455	Jehovah's Witnesses,	
		Logothetopoulos pack 458
complications 456	anemia management in 591	low resource settings,
damage to during hyogastric	antenatal management 589	adequacy of delivery setting 540
artery ligation 446	blood transfusions and 587–92	benefit of non-pneumatic anti-shock
indications for 457	cell salvage methods in 579	garment in 320
procedures for 455, 456	intraoperative cell salvage for 950	community-based continuum of
prophylactic 442	management in labor 589	care 555–60
reasons for failure 446	management of hemorrhage in 590	emergency care in 559
reproductive function after	use of cryoprecipitate in 33	FIGO guidelines for PPH
445, 457	use of fibrin sealants in 475	prevention and treatment
surgeon position for 446	view of medicine and blood 587	in 607–18
	view of incurring and blood 307	
therapeutic 443		health care infrastructure in 542
ureteric damage during 446	1	management of PPH in 539–44
International Classification of Diseases,	kanga,	measurement of blood loss using
PPH coding 155	blood loss assessment from 353, 557	BRASSS-V drape in 85
International Classification of Diseases,	in Tanzania 83	medical management of PPH 540
changes in coding 157	kapulana, blood loss assessment from 354	misoprostol use in 285

severe acute maternal morbidity in	denominators used in calculation of	with misoprostol for medical
501	135	termination of pregnancy
surgical management of PPH 541	elimination in UK 165	276
use of pelvic pressure pack during	from emergency hysterectomy 458	Millennium Development Goal 5 120,
transport to tertiary care	from PPH in developed countries	284
460	153	misoprostol 4, 114, 275–80
lower genital tract bleeding 193–8	from PPH in UK 162–7	administration route and side-effects
lower uterine segment, postpartum	geographical variations in 170	299
pathology of 491–3	globally 135	cf conventional oxytocics 279
lower uterine vascular supply,	historical perspective 545	cf oxytocin 104, 284, 296
anatomy of 19–23	historical rates 55	efficacy 297
dissections showing 22	impact of new hospital systems on	cf placebo/no uterotonic 104
	345	chemical structure 275
	in 19th century England 355	community-based continuum of care
macrosomia 58, 140	in Africa 136	use 556
magnetic resonance imaging (MRI),	in France 136	cost effectiveness of 541
before embolization to identify	in placenta accreta 247	costs of 358
placental abnormalities 406	in UK 135	countries in which it is approved for
for placenta accreta 250	in USA 136	use 70
guidelines for placental 17	inaccurate blood loss estimation 164	deaths averted by 286
imaging for placental invasion 267	increase in Illinois 348	description 259, 275
Malawi, MamaNatalie® newborn	instrumental delivery 164	efficacy at community level 353
simulator trials in 603	leading cause 55	existing evidence for use of 66
Mali, AMTSL in 123	morbidity-mortality continuum 500	FIGO guidelines on 609, 612
malignant hypertension, litigation 533	non-pneumatic anti-shock garment	for cervical priming 279
MamaNatalie® birthing simulator 602-3	use 325	for uterine atony 357
massive transfusion,	placenta previa 163	labor induction 285
battlefield evidence 34-5, 46	placental abruption 162	off-label use 284
complications 27	prevention strategies in low resource	overview of studies of its use in PPH
in PPH 34–37	settings 542–4	289-95
in trauma 35	refusal of care and 165	pharmacokinetics 275
protocols 26, 36	release for hospital form for women	plus oxytocin 300
transfusions after 27	refusing transfusion 600	recommendations for use in PPH
maternal circulation to placenta 180	risk in Jehovah's Witnesses 588	295
maternal morbidity,	uterine rupture 164	safe dose by gestation 278
after peripartum hysterectomy 462	Matthew Duncan separation method 95	safety 278
after placenta accreta management	May-Hegglin anomaly 208	side-effects 276
243, 244	mechanical heart valve prostheses 207	sublingual for PPH 296-301
communication and 308, 309	medical anti-shock trousers 318	use after intrauterine fetal death 286
denominators used in calculation of	medical termination of pregnancy using	use by trained birth attendants 284
135	misoprostol 276, 277, 285, 286	use for medical termination of
determination of near misses 147	medical therapy 355–9	pregnancy 276
determining incidence 147-51	menstruation after embolization 411	use in first trimester 276, 285
hospital-based near miss research	methotrexate,	use in low resource settings 285, 540
150	cf mifepristone/misoprostol in	use in out-of-hospital deliveries 573
in Africa 137	placenta accreta 260	use in placenta accreta 259-61
in Australia 137	for abdominal pregnancy 586	use in practice 284–7
in Canada 137	for conservative management of	use in second trimester 277, 286
in England 137	placenta accreta 454	use in third stage of labor 279
in Scotland 136	for placenta accreta 244, 253	use in third trimester 278, 286
in USA 137	with misoprostol for medical	mobile phone use to distribute
morbidity-mortality continuum 500	termination of pregnancy	reproductive health information
near miss data collection in Canada	276	287
148	methylergometrine, warning on use 66	moda, blood loss assessment from 354
non-pneumatic anti-shock garment	Mexico,	Modified Early Obstetric Warning Scores
use 325	cost-effectiveness of carbetocin study	74, 75, 359
organ-dysfunction approach to	in 366	morbidity-mortality continuum 500
maternal near miss 148	non-pneumatic anti-shock garment	morbidly adherent placenta, see placenta
out-of-hospital deliveries and 573	studies in 332	accreta, placenta increta, placenta
risk in Jehovah's Witnesses 588	microangiopathy in thrombocytopenia	percreta
severe acute 499–511	202-4	motor vehicle accidents and abdominal
maternal mortality,	microchimerism 27	trauma 189–91
after peripartum hysterectomy 462	midwife,	multidisciplinary teams,
after uterine rupture 188	care after PPH by 551	and reduction of severe acute
age and 170	debriefing 552	maternal morbidity 510
antenatal care and 165	documentation 551	for placenta accreta management 251
case reports from history 546-8	management of PPH by 551	multigate spectral Doppler analysis 89, 90
coagulopathy 164	role in PPH prevention 549–51	multiple gestation,
communication and 308, 309	training of 552	placenta previa risk 231
improvements and 166	mifepristone,	PPH incidence 152, 156
deaths averted by misoprostol use	description 259	PPH risk 140
286	use in first trimester 286	Muskoka initiative 68

myonecrosis 492

declining rate in Japan 169-74

National Patient Safety Agency	oxytocin 101–4	permanent embolic materials 400
recommendations 166	after successful tamponade 380	pharmacokinetics of misoprostol 275
near misses,	cf carbetocin 362, 363	physiology,
cf severe acute maternal morbidity 499	cf misoprostol 104, 279, 284, 296	adaptations during pregnancy 82
	efficacy 297 chemical structure 362	of hypovolemic shock 332 of internal iliac artery ligation 442
determining incidence 147–51 necrosis at cesarean section scar site 492	FIGO guidelines on use 612	placenta,
NeoNatalie® newborn simulator 603	for uterine atony 356–7	abnormal in S1 and S2 segments 22
neovascularization,	limitations of use 361	adherent 10
anastomotic levels of 266	plus misoprostol 300	guidelines for MRI in 17
in placental invasion 265	prophylactic use plus misoprostol	bipartite 236
Nepal, misoprostol use in 557	301	classical methods of delivery 95
Nigeria,	role in third stage of labor 95	examination of 4, 119
blood loss assessment by moda 354	side-effects 356	FIGO guidelines on facilitation of
misoprostol use in 286, 287	synthesis 355	delivery 611
non-pneumatic anti-shock garment	use in first stage management and	growth and maturation of 180
trials in 322–7	PPH 157	guidelines for placental MRI 17
use in 559	use in secondary PPH 469	invasive pattern of human
Nitabuch's layer 264	use in third stage of labor 102, 103,	placentation 56
non-governmental organizations 543	104	lacunae in and diagnosis of placenta
non-pneumatic anti-shock garment 558 application 321	vs. ergometrine plus oxytocin 103	accreta 241
description of 318	vs. ergot alkaloids 102 vs. no uterotonics 102	lower segment implantation and PPH 97
FIGO guidelines on 616	oxytocin agonists 102	management for abdominal
for non-atonic PPH 326	oxytochi agomsis 102	pregnancy 585
intra-abdominal pressure and 338		management of morbidly adherent
manufacture 328	packed red blood cells 30	163
mechanisms of action 331-9	packing 9	manual removal, EUPHRATES
patient management in 322	for vaginal tears 195	consensus on 111
pelvic blood flow and 337	in hemostatic resuscitation 25	maternal circulation to 180
physiologic studies of 335	pelvic pressure pack 458-60	mature 180
removal 322	success of 459	pathology 496
suggested protocol for use 320	uterine 379	and final blood loss volume
trials 318–28	Pakistan,	373
for use during transport 327	misoprostol use in 557	rare abnormal shapes 236
in Mexico 332	non-pneumatic anti-shock garment	removal in acute uterine inversion
in Zambia 327, 332	trials in 322	186
in Zimbabwe 327, 332	parallel blood flow circuits in uterus 181	retained 494
uses duraines transportation 21E 210	- manifer	matain ad tissus on manhum as 152
use during transportation 315, 318,	parity,	retained tissue or membranes 453
454	placenta previa risk 231	retention prevalence 138
454 use in developed countries 328	placenta previa risk 231 PPH risk 139	retention prevalence 138 separation and uterine activity 94
454 use in developed countries 328 use in Egypt 322–7	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology,	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6
454 use in developed countries 328 use in Egypt 322–7	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7 use in Pakistan 322	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97 of uterine muscle 94	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive coagulopathy 205
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7 use in Pakistan 322 use with other therapies 327	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97 of uterine muscle 94 patient safety teams 342 patient transfer 5 barriers to 559	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive coagulopathy 205 balloon catheter placement and
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7 use in Pakistan 322 use with other therapies 327 variation in strength of appliers and	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97 of uterine muscle 94 patient safety teams 342 patient transfer 5 barriers to 559 in low resource settings 543	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive coagulopathy 205 balloon catheter placement and embolization in 408 compression suture for 436 diagnosis 247
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7 use in Pakistan 322 use with other therapies 327 variation in strength of appliers and efficacy 338–9	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97 of uterine muscle 94 patient safety teams 342 patient transfer 5 barriers to 559 in low resource settings 543 non-pneumatic anti-shock garment	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive coagulopathy 205 balloon catheter placement and embolization in 408 compression suture for 436 diagnosis 247 effect of screening on management
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7 use in Pakistan 322 use with other therapies 327 variation in strength of appliers and efficacy 338–9 noradrenergic receptors 522	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97 of uterine muscle 94 patient safety teams 342 patient transfer 5 barriers to 559 in low resource settings 543 non-pneumatic anti-shock garment and 315, 318, 325, 327	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive coagulopathy 205 balloon catheter placement and embolization in 408 compression suture for 436 diagnosis 247 effect of screening on management in a UK hospital 247–56
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7 use in Pakistan 322 use with other therapies 327 variation in strength of appliers and efficacy 338–9 noradrenergic receptors 522 Obstetric Hemorrhage Education Project	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97 of uterine muscle 94 patient safety teams 342 patient transfer 5 barriers to 559 in low resource settings 543 non-pneumatic anti-shock garment and 315, 318, 325, 327 problems and maternal morbidity	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive coagulopathy 205 balloon catheter placement and embolization in 408 compression suture for 436 diagnosis 247 effect of screening on management in a UK hospital 247–56 elective cesarean for 10
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7 use in Pakistan 322 use with other therapies 327 variation in strength of appliers and efficacy 338–9 noradrenergic receptors 522 Obstetric Hemorrhage Education Project 348–50	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97 of uterine muscle 94 patient safety teams 342 patient transfer 5 barriers to 559 in low resource settings 543 non-pneumatic anti-shock garment and 315, 318, 325, 327 problems and maternal morbidity and mortality 308	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive coagulopathy 205 balloon catheter placement and embolization in 408 compression suture for 436 diagnosis 247 effect of screening on management in a UK hospital 247–56 elective cesarean for 10 emergency cesarean for 11
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7 use in Pakistan 322 use with other therapies 327 variation in strength of appliers and efficacy 338–9 noradrenergic receptors 522 Obstetric Hemorrhage Education Project 348–50 obstetric hemorrhage equipment tray	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97 of uterine muscle 94 patient safety teams 342 patient transfer 5 barriers to 559 in low resource settings 543 non-pneumatic anti-shock garment and 315, 318, 325, 327 problems and maternal morbidity and mortality 308 reduction of severe acute maternal	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive coagulopathy 205 balloon catheter placement and embolization in 408 compression suture for 436 diagnosis 247 effect of screening on management in a UK hospital 247–56 elective cesarean for 10 emergency cesarean for 11 fertility after 260
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7 use in Pakistan 322 use with other therapies 327 variation in strength of appliers and efficacy 338–9 noradrenergic receptors 522 Obstetric Hemorrhage Education Project 348–50 obstetric hemorrhage equipment tray 314	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97 of uterine muscle 94 patient safety teams 342 patient transfer 5 barriers to 559 in low resource settings 543 non-pneumatic anti-shock garment and 315, 318, 325, 327 problems and maternal morbidity and mortality 308 reduction of severe acute maternal morbidity and 510	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive coagulopathy 205 balloon catheter placement and embolization in 408 compression suture for 436 diagnosis 247 effect of screening on management in a UK hospital 247–56 elective cesarean for 10 emergency cesarean for 11 fertility after 260 imaging of 248–50
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7 use in Pakistan 322 use with other therapies 327 variation in strength of appliers and efficacy 338–9 noradrenergic receptors 522 Obstetric Hemorrhage Education Project 348–50 obstetric hemorrhage equipment tray 314 obstetric rapid response team 342	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97 of uterine muscle 94 patient safety teams 342 patient transfer 5 barriers to 559 in low resource settings 543 non-pneumatic anti-shock garment and 315, 318, 325, 327 problems and maternal morbidity and mortality 308 reduction of severe acute maternal morbidity and 510 pelvic anastomoses 442	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive coagulopathy 205 balloon catheter placement and embolization in 408 compression suture for 436 diagnosis 247 effect of screening on management in a UK hospital 247–56 elective cesarean for 10 emergency cesarean for 11 fertility after 260 imaging of 248–50 guidelines for MRI in 17
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7 use in Pakistan 322 use with other therapies 327 variation in strength of appliers and efficacy 338–9 noradrenergic receptors 522 Obstetric Hemorrhage Education Project 348–50 obstetric hemorrhage equipment tray 314 obstetric rapid response team 342 obstructed labor and uterine rupture 188	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97 of uterine muscle 94 patient safety teams 342 patient transfer 5 barriers to 559 in low resource settings 543 non-pneumatic anti-shock garment and 315, 318, 325, 327 problems and maternal morbidity and mortality 308 reduction of severe acute maternal morbidity and 510 pelvic anastomoses 442 pelvic pressure pack 458–60	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive coagulopathy 205 balloon catheter placement and embolization in 408 compression suture for 436 diagnosis 247 effect of screening on management in a UK hospital 247–56 elective cesarean for 10 emergency cesarean for 11 fertility after 260 imaging of 248–50 guidelines for MRI in 17 in UK 163
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7 use in Pakistan 322 use with other therapies 327 variation in strength of appliers and efficacy 338–9 noradrenergic receptors 522 Obstetric Hemorrhage Education Project 348–50 obstetric hemorrhage equipment tray 314 obstetric rapid response team 342	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97 of uterine muscle 94 patient safety teams 342 patient transfer 5 barriers to 559 in low resource settings 543 non-pneumatic anti-shock garment and 315, 318, 325, 327 problems and maternal morbidity and mortality 308 reduction of severe acute maternal morbidity and 510 pelvic anastomoses 442 pelvic pressure pack 458–60 for obstetric hemorrhage equipment	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive coagulopathy 205 balloon catheter placement and embolization in 408 compression suture for 436 diagnosis 247 effect of screening on management in a UK hospital 247–56 elective cesarean for 10 emergency cesarean for 11 fertility after 260 imaging of 248–50 guidelines for MRI in 17 in UK 163 incidence 240
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7 use in Pakistan 322 use with other therapies 327 variation in strength of appliers and efficacy 338–9 noradrenergic receptors 522 Obstetric Hemorrhage Education Project 348–50 obstetric hemorrhage equipment tray 314 obstetric rapid response team 342 obstructed labor and uterine rupture 188 one-step conservative surgery for placenta accreta 267–70	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97 of uterine muscle 94 patient safety teams 342 patient transfer 5 barriers to 559 in low resource settings 543 non-pneumatic anti-shock garment and 315, 318, 325, 327 problems and maternal morbidity and mortality 308 reduction of severe acute maternal morbidity and 510 pelvic anastomoses 442 pelvic pressure pack 458–60 for obstetric hemorrhage equipment tray 315	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive coagulopathy 205 balloon catheter placement and embolization in 408 compression suture for 436 diagnosis 247 effect of screening on management in a UK hospital 247–56 elective cesarean for 10 emergency cesarean for 11 fertility after 260 imaging of 248–50 guidelines for MRI in 17 in UK 163
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7 use in Pakistan 322 use with other therapies 327 variation in strength of appliers and efficacy 338–9 noradrenergic receptors 522 Obstetric Hemorrhage Education Project 348–50 obstetric hemorrhage equipment tray 314 obstetric rapid response team 342 obstructed labor and uterine rupture 188 one-step conservative surgery for placenta	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97 of uterine muscle 94 patient safety teams 342 patient transfer 5 barriers to 559 in low resource settings 543 non-pneumatic anti-shock garment and 315, 318, 325, 327 problems and maternal morbidity and mortality 308 reduction of severe acute maternal morbidity and 510 pelvic anastomoses 442 pelvic pressure pack 458–60 for obstetric hemorrhage equipment	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive coagulopathy 205 balloon catheter placement and embolization in 408 compression suture for 436 diagnosis 247 effect of screening on management in a UK hospital 247–56 elective cesarean for 10 emergency cesarean for 11 fertility after 260 imaging of 248–50 guidelines for MRI in 17 in UK 163 incidence 240 increasing 247, 263
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7 use in Pakistan 322 use with other therapies 327 variation in strength of appliers and efficacy 338–9 noradrenergic receptors 522 Obstetric Hemorrhage Education Project 348–50 obstetric hemorrhage equipment tray 314 obstetric rapid response team 342 obstructed labor and uterine rupture 188 one-step conservative surgery for placenta accreta 267–70 organ-dysfunction approach to maternal	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97 of uterine muscle 94 patient safety teams 342 patient transfer 5 barriers to 559 in low resource settings 543 non-pneumatic anti-shock garment and 315, 318, 325, 327 problems and maternal morbidity and mortality 308 reduction of severe acute maternal morbidity and 510 pelvic anastomoses 442 pelvic pressure pack 458–60 for obstetric hemorrhage equipment tray 315 pelvic vascular supply 439	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive coagulopathy 205 balloon catheter placement and embolization in 408 compression suture for 436 diagnosis 247 effect of screening on management in a UK hospital 247–56 elective cesarean for 10 emergency cesarean for 11 fertility after 260 imaging of 248–50 guidelines for MRI in 17 in UK 163 incidence 240 increasing 247, 263 management,
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7 use in Pakistan 322 use with other therapies 327 variation in strength of appliers and efficacy 338–9 noradrenergic receptors 522 Obstetric Hemorrhage Education Project 348–50 obstetric hemorrhage equipment tray 314 obstetric rapid response team 342 obstructed labor and uterine rupture 188 one-step conservative surgery for placenta accreta 267–70 organ-dysfunction approach to maternal near miss 148	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97 of uterine muscle 94 patient safety teams 342 patient transfer 5 barriers to 559 in low resource settings 543 non-pneumatic anti-shock garment and 315, 318, 325, 327 problems and maternal morbidity and mortality 308 reduction of severe acute maternal morbidity and 510 pelvic anastomoses 442 pelvic pressure pack 458–60 for obstetric hemorrhage equipment tray 315 pelvic vascular supply 439 anatomy on imaging 399–400 pelvic vessels, abnormal vasculature and secondary	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive coagulopathy 205 balloon catheter placement and embolization in 408 compression suture for 436 diagnosis 247 effect of screening on management in a UK hospital 247–56 elective cesarean for 10 emergency cesarean for 11 fertility after 260 imaging of 248–50 guidelines for MRI in 17 in UK 163 incidence 240 increasing 247, 263 management, algorithm for 243 conservative 252 conservative leaving placenta in
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7 use in Pakistan 322 use with other therapies 327 variation in strength of appliers and efficacy 338–9 noradrenergic receptors 522 Obstetric Hemorrhage Education Project 348–50 obstetric hemorrhage equipment tray 314 obstetric rapid response team 342 obstructed labor and uterine rupture 188 one-step conservative surgery for placenta accreta 267–70 organ-dysfunction approach to maternal near miss 148 out-of-hospital deliveries 571–4 global rates 572 planned vs. unplanned 572	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97 of uterine muscle 94 patient safety teams 342 patient transfer 5 barriers to 559 in low resource settings 543 non-pneumatic anti-shock garment and 315, 318, 325, 327 problems and maternal morbidity and mortality 308 reduction of severe acute maternal morbidity and 510 pelvic anastomoses 442 pelvic pressure pack 458–60 for obstetric hemorrhage equipment tray 315 pelvic vascular supply 439 anatomy on imaging 399–400 pelvic vessels, abnormal vasculature and secondary PPH 467	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive coagulopathy 205 balloon catheter placement and embolization in 408 compression suture for 436 diagnosis 247 effect of screening on management in a UK hospital 247–56 elective cesarean for 10 emergency cesarean for 11 fertility after 260 imaging of 248–50 guidelines for MRI in 17 in UK 163 incidence 240 increasing 247, 263 management, algorithm for 243 conservative 252 conservative leaving placenta in uterus 242
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7 use in Pakistan 322 use with other therapies 327 variation in strength of appliers and efficacy 338–9 noradrenergic receptors 522 Obstetric Hemorrhage Education Project 348–50 obstetric hemorrhage equipment tray 314 obstetric rapid response team 342 obstructed labor and uterine rupture 188 one-step conservative surgery for placenta accreta 267–70 organ-dysfunction approach to maternal near miss 148 out-of-hospital deliveries 571–4 global rates 572 planned vs. unplanned 572 PPH and 573	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97 of uterine muscle 94 patient safety teams 342 patient transfer 5 barriers to 559 in low resource settings 543 non-pneumatic anti-shock garment and 315, 318, 325, 327 problems and maternal morbidity and mortality 308 reduction of severe acute maternal morbidity and 510 pelvic anastomoses 442 pelvic pressure pack 458–60 for obstetric hemorrhage equipment tray 315 pelvic vascular supply 439 anatomy on imaging 399–400 pelvic vessels, abnormal vasculature and secondary PPH 467 pelvic artery embolization in	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive coagulopathy 205 balloon catheter placement and embolization in 408 compression suture for 436 diagnosis 247 effect of screening on management in a UK hospital 247–56 elective cesarean for 10 emergency cesarean for 11 fertility after 260 imaging of 248–50 guidelines for MRI in 17 in UK 163 incidence 240 increasing 247, 263 management, algorithm for 243 conservative 252 conservative leaving placenta in uterus 242 conservative with adjuvant
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7 use in Pakistan 322 use with other therapies 327 variation in strength of appliers and efficacy 338–9 noradrenergic receptors 522 Obstetric Hemorrhage Education Project 348–50 obstetric hemorrhage equipment tray 314 obstetric rapid response team 342 obstructed labor and uterine rupture 188 one-step conservative surgery for placenta accreta 267–70 organ-dysfunction approach to maternal near miss 148 out-of-hospital deliveries 571–4 global rates 572 planned vs. unplanned 572 PPH and 573 PPH risk 574	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97 of uterine muscle 94 patient safety teams 342 patient transfer 5 barriers to 559 in low resource settings 543 non-pneumatic anti-shock garment and 315, 318, 325, 327 problems and maternal morbidity and mortality 308 reduction of severe acute maternal morbidity and 510 pelvic anastomoses 442 pelvic pressure pack 458–60 for obstetric hemorrhage equipment tray 315 pelvic vascular supply 439 anatomy on imaging 399–400 pelvic vessels, abnormal vasculature and secondary PPH 467 pelvic artery embolization in placenta accreta 253	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive coagulopathy 205 balloon catheter placement and embolization in 408 compression suture for 436 diagnosis 247 effect of screening on management in a UK hospital 247–56 elective cesarean for 10 emergency cesarean for 11 fertility after 260 imaging of 248–50 guidelines for MRI in 17 in UK 163 incidence 240 increasing 247, 263 management, algorithm for 243 conservative 252 conservative leaving placenta in uterus 242 conservative with adjuvant therapy 244
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7 use in Pakistan 322 use with other therapies 327 variation in strength of appliers and efficacy 338–9 noradrenergic receptors 522 Obstetric Hemorrhage Education Project 348–50 obstetric hemorrhage equipment tray 314 obstetric rapid response team 342 obstructed labor and uterine rupture 188 one-step conservative surgery for placenta accreta 267–70 organ-dysfunction approach to maternal near miss 148 out-of-hospital deliveries 571–4 global rates 572 planned vs. unplanned 572 PPH and 573 PPH risk 574 ovarian arteries, prepregnancy	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97 of uterine muscle 94 patient safety teams 342 patient transfer 5 barriers to 559 in low resource settings 543 non-pneumatic anti-shock garment and 315, 318, 325, 327 problems and maternal morbidity and mortality 308 reduction of severe acute maternal morbidity and 510 pelvic anastomoses 442 pelvic pressure pack 458–60 for obstetric hemorrhage equipment tray 315 pelvic vascular supply 439 anatomy on imaging 399–400 pelvic vessels, abnormal vasculature and secondary PPH 467 pelvic artery embolization in placenta accreta 253 vascular branching patterns in 399	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive coagulopathy 205 balloon catheter placement and embolization in 408 compression suture for 436 diagnosis 247 effect of screening on management in a UK hospital 247–56 elective cesarean for 10 emergency cesarean for 11 fertility after 260 imaging of 248–50 guidelines for MRI in 17 in UK 163 incidence 240 increasing 247, 263 management, algorithm for 243 conservative 252 conservative leaving placenta in uterus 242 conservative with adjuvant therapy 244 conservative with resection of
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7 use in Pakistan 322 use with other therapies 327 variation in strength of appliers and efficacy 338–9 noradrenergic receptors 522 Obstetric Hemorrhage Education Project 348–50 obstetric hemorrhage equipment tray 314 obstetric rapid response team 342 obstructed labor and uterine rupture 188 one-step conservative surgery for placenta accreta 267–70 organ-dysfunction approach to maternal near miss 148 out-of-hospital deliveries 571–4 global rates 572 planned vs. unplanned 572 PPH and 573 PPH risk 574 ovarian arteries, prepregnancy hemodynamics 178	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97 of uterine muscle 94 patient safety teams 342 patient transfer 5 barriers to 559 in low resource settings 543 non-pneumatic anti-shock garment and 315, 318, 325, 327 problems and maternal morbidity and mortality 308 reduction of severe acute maternal morbidity and 510 pelvic anastomoses 442 pelvic pressure pack 458–60 for obstetric hemorrhage equipment tray 315 pelvic vascular supply 439 anatomy on imaging 399–400 pelvic vessels, abnormal vasculature and secondary PPH 467 pelvic artery embolization in placenta accreta 253 vascular branching patterns in 399 perineal tear repair 195	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive coagulopathy 205 balloon catheter placement and embolization in 408 compression suture for 436 diagnosis 247 effect of screening on management in a UK hospital 247–56 elective cesarean for 10 emergency cesarean for 11 fertility after 260 imaging of 248–50 guidelines for MRI in 17 in UK 163 incidence 240 increasing 247, 263 management, algorithm for 243 conservative 252 conservative leaving placenta in uterus 242 conservative with adjuvant therapy 244 conservative with resection of placental bed 244
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7 use in Pakistan 322 use with other therapies 327 variation in strength of appliers and efficacy 338–9 noradrenergic receptors 522 Obstetric Hemorrhage Education Project 348–50 obstetric hemorrhage equipment tray 314 obstetric rapid response team 342 obstructed labor and uterine rupture 188 one-step conservative surgery for placenta accreta 267–70 organ-dysfunction approach to maternal near miss 148 out-of-hospital deliveries 571–4 global rates 572 planned vs. unplanned 572 PPH and 573 PPH risk 574 ovarian arteries, prepregnancy hemodynamics 178 ovarian vein,	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97 of uterine muscle 94 patient safety teams 342 patient transfer 5 barriers to 559 in low resource settings 543 non-pneumatic anti-shock garment and 315, 318, 325, 327 problems and maternal morbidity and mortality 308 reduction of severe acute maternal morbidity and 510 pelvic anastomoses 442 pelvic pressure pack 458–60 for obstetric hemorrhage equipment tray 315 pelvic vascular supply 439 anatomy on imaging 399–400 pelvic vessels, abnormal vasculature and secondary PPH 467 pelvic artery embolization in placenta accreta 253 vascular branching patterns in 399 perineal tear repair 195 peripartum hysterectomy 462–64	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive coagulopathy 205 balloon catheter placement and embolization in 408 compression suture for 436 diagnosis 247 effect of screening on management in a UK hospital 247–56 elective cesarean for 10 emergency cesarean for 11 fertility after 260 imaging of 248–50 guidelines for MRI in 17 in UK 163 incidence 240 increasing 247, 263 management, algorithm for 243 conservative 252 conservative leaving placenta in uterus 242 conservative with adjuvant therapy 244 conservative with resection of placental bed 244 emergency 244–5
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7 use in Pakistan 322 use with other therapies 327 variation in strength of appliers and efficacy 338–9 noradrenergic receptors 522 Obstetric Hemorrhage Education Project 348–50 obstetric hemorrhage equipment tray 314 obstetric rapid response team 342 obstructed labor and uterine rupture 188 one-step conservative surgery for placenta accreta 267–70 organ-dysfunction approach to maternal near miss 148 out-of-hospital deliveries 571–4 global rates 572 planned vs. unplanned 572 PPH and 573 PPH risk 574 ovarian arteries, prepregnancy hemodynamics 178 ovarian vein, diameter decrease after pregnancy	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97 of uterine muscle 94 patient safety teams 342 patient transfer 5 barriers to 559 in low resource settings 543 non-pneumatic anti-shock garment and 315, 318, 325, 327 problems and maternal morbidity and mortality 308 reduction of severe acute maternal morbidity and 510 pelvic anastomoses 442 pelvic pressure pack 458–60 for obstetric hemorrhage equipment tray 315 pelvic vascular supply 439 anatomy on imaging 399–400 pelvic vessels, abnormal vasculature and secondary PPH 467 pelvic artery embolization in placenta accreta 253 vascular branching patterns in 399 perineal tear repair 195 peripartum hysterectomy 462–64 impact of new hospital systems on	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive coagulopathy 205 balloon catheter placement and embolization in 408 compression suture for 436 diagnosis 247 effect of screening on management in a UK hospital 247–56 elective cesarean for 10 emergency cesarean for 11 fertility after 260 imaging of 248–50 guidelines for MRI in 17 in UK 163 incidence 240 increasing 247, 263 management, algorithm for 243 conservative 252 conservative leaving placenta in uterus 242 conservative with adjuvant therapy 244 conservative with resection of placental bed 244 emergency 244–5 in UK 247–56
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7 use in Pakistan 322 use with other therapies 327 variation in strength of appliers and efficacy 338–9 noradrenergic receptors 522 Obstetric Hemorrhage Education Project 348–50 obstetric hemorrhage equipment tray 314 obstetric rapid response team 342 obstructed labor and uterine rupture 188 one-step conservative surgery for placenta accreta 267–70 organ-dysfunction approach to maternal near miss 148 out-of-hospital deliveries 571–4 global rates 572 planned vs. unplanned 572 PPH and 573 PPH risk 574 ovarian arteries, prepregnancy hemodynamics 178 ovarian vein,	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97 of uterine muscle 94 patient safety teams 342 patient transfer 5 barriers to 559 in low resource settings 543 non-pneumatic anti-shock garment and 315, 318, 325, 327 problems and maternal morbidity and mortality 308 reduction of severe acute maternal morbidity and 510 pelvic anastomoses 442 pelvic pressure pack 458–60 for obstetric hemorrhage equipment tray 315 pelvic vascular supply 439 anatomy on imaging 399–400 pelvic vessels, abnormal vasculature and secondary PPH 467 pelvic artery embolization in placenta accreta 253 vascular branching patterns in 399 perineal tear repair 195 peripartum hysterectomy 462–64	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive coagulopathy 205 balloon catheter placement and embolization in 408 compression suture for 436 diagnosis 247 effect of screening on management in a UK hospital 247–56 elective cesarean for 10 emergency cesarean for 11 fertility after 260 imaging of 248–50 guidelines for MRI in 17 in UK 163 incidence 240 increasing 247, 263 management, algorithm for 243 conservative 252 conservative leaving placenta in uterus 242 conservative with adjuvant therapy 244 conservative with resection of placental bed 244 emergency 244–5
use in developed countries 328 use in Egypt 322–7 use in low-resource settings 320 use in Nigeria 322–7 use in Pakistan 322 use with other therapies 327 variation in strength of appliers and efficacy 338–9 noradrenergic receptors 522 Obstetric Hemorrhage Education Project 348–50 obstetric repid response team 342 obstructed labor and uterine rupture 188 one-step conservative surgery for placenta accreta 267–70 organ-dysfunction approach to maternal near miss 148 out-of-hospital deliveries 571–4 global rates 572 planned vs. unplanned 572 PPH and 573 PPH risk 574 ovarian arteries, prepregnancy hemodynamics 178 ovarian vein, diameter decrease after pregnancy 182	placenta previa risk 231 PPH risk 139 pathology of postpartum uterus 489–97 pathophysiology, of uterine atony 97 of uterine muscle 94 patient safety teams 342 patient transfer 5 barriers to 559 in low resource settings 543 non-pneumatic anti-shock garment and 315, 318, 325, 327 problems and maternal morbidity and mortality 308 reduction of severe acute maternal morbidity and 510 pelvic anastomoses 442 pelvic pressure pack 458–60 for obstetric hemorrhage equipment tray 315 pelvic vascular supply 439 anatomy on imaging 399–400 pelvic vessels, abnormal vasculature and secondary PPH 467 pelvic artery embolization in placenta accreta 253 vascular branching patterns in 399 perineal tear repair 195 peripartum hysterectomy 462–64 impact of new hospital systems on incidence 346	retention prevalence 138 separation and uterine activity 94 succenturiate lobe of 236 placenta accreta 57, 235–6 as a cause of consumptive coagulopathy 205 balloon catheter placement and embolization in 408 compression suture for 436 diagnosis 247 effect of screening on management in a UK hospital 247–56 elective cesarean for 10 emergency cesarean for 11 fertility after 260 imaging of 248–50 guidelines for MRI in 17 in UK 163 incidence 240 increasing 247, 263 management, algorithm for 243 conservative 252 conservative leaving placenta in uterus 242 conservative with adjuvant therapy 244 conservative with resection of placental bed 244 emergency 244–5 in UK 247–56 intraoperative 254

of acutely presenting cases 253	preparation protocols for	in failed sequential instrumental
one-step conservative surgery	management 343	delivery/emergency
263–71	risk factors for 231	cesarean 9
outpatient 251	substandard management 163	in other animals 58
postpartum 256	surgical management 453	in uterine inversion 15
timing of surgery 267	topical hemostatic agents 480	instrumental delivery and 5
using mifepristone/	use of fibrin sealants in 476	intensive care management 520-5
misoprostol 259-61	placental abnormalities 227-36	link with invasive placentation 57
when diagnosed after delivery	placental abruption 57, 227-30	litigation after 527-35
244–5	after blunt abdominal trauma 190	longstanding history of 60
when diagnosed antenatally	as a cause of consumptive	management in low resource settings
250	coagulopathy 205	539–44
with hysterectomy 242	concealed cf revealed 228	management model 24–7
without hysterectomy 242-4	diagnosis 227	management under different
management of 240-5	grading 228	scenarios 3–18
maternal mortality 247	incidence 227	massive transfusion in 34–7
morphological classification 264	management,	measurement methodologies 65
multidisciplinary team management	by immediate delivery 229	misoprostol therapy 279, 289–95,
checklist 254	expectant 230	296–301
operative delivery of infant 255	of complications 230	modern teaching/learning modalities
pathophysiology of 98 peripartum hysterectomy and 463	peripartum hysterectomy and 463 risk factors 227, 228	for PPH management 514–18
postoperative thromboprophylaxis	substandard management 162	new approaches to transfusion in
256	tocolytic masking of 191	48–51
postpartum pathology of 493	triple tourniquet for 451	obstetric hemorrhage equipment tray
PPH incidence and 156	placental invasion description 263–4	contents 314
pregnancy after 263	placental lacunae 248	pathophysiology of 97
prenatal screening for 240–1	placental separation mechanics 182	prevention of 66
preoperative checklist 254	placental-vesical system	EUPHRATES consensus on
preparation protocols for	(neovascularization) 266	109–11
management 343	placentation,	in UK 166
prevalence 138	impaired 57	initiatives 67
recommended protocol for 410	invasive pattern in humans cf other	projects in Japan 172
risk factors 240, 248	primates 56	progressive intermittent 12
secondary PPH after 466	plasma,	secondary 466–71
surgical management 453	cf cryoprecipitate and fibrinogen 50	severe acute maternal morbidity
systems of neovascularization in 266	dose 33	499–511
topical hemostatic agents for 485	for transfusion 32–3	statistics 64
unexpected diagnosis 11	volume changes 84	transfusion management of 30-41
placenta increta 235–6	platelets,	vaginal delivery and 4
balloon catheter placement in 409	congenital platelet disorders 208	variations in definition 155
compression suture for 436	dose 34	vascular malformations and 218-24
prevalence 138	for transfusion 33–4	WHO guidance on prevention 121
recommended protocol for 410	pneumatic anti-shock garment 318, 319	postsurgical packing 458
secondary PPH after 466	animal studies 333	post-transfusion purpura 27
placenta membranacea 236	current status of 320	PRactical Obstetric MultiProfessional
placenta percreta 57, 235–6	human studies 334	Training (PROMPT) 565
compression suture for 436	physiologic studies of 333	pre-eclampsia 57, 82
one-step conservative surgery 255	theoretical model of function 333	and HELLP syndrome 203
postpartum pathology of 493	POPPHI 121–3	and PPH risk 140
prevalence 138	postpartum hemorrhage (PPH),	as a cause of consumptive
-	accurate rate determination 152–8	1
recommended protocol for 410 secondary PPH after 466	after elective cesarean section 7	coagulopathy 205
		pregnancy,
placenta previa 231–5	after forceps delivery 6	after placenta accreta 263
after cesarean section care bundle	algorithm for management of 196	changes in coagulation system during
166	autopsy after 496	199
as risk factor for placenta accreta	case reports 546–8	uterine arteries during 182
240	causes 130–1, 433	preterm labor after blunt abdominal
clinical presentation 231	classification 82, 129–32	trauma 190
compression suture for 434	common scenarios 3–18	prevention initiatives 67
diagnosis 231	concealed 13	Prevention of PPH Initiative 121–3
imaging for 232	declining mortality in Japan 169–74	previous PPH and PPH incidence 156
excessive bleeding at cesarean section	definition 64, 81, 133	professional organizations, role in PPH
and 449	early fibrinogen use 45–7	prevention 67
grading 231	etiology 65	progressive intermittent PPH 12
incidence 231	EUPHRATES definition 109	prolonged pregnancy and PPH risk 140
management,	European consensus on prevention	prophylaxis,
cesarean section for 234–5	and management of 109–12	antibiotic use and pelvic packing
expectant 233	evolution and 55-61	460
procedure used 234	history of 545	antibiotic use in placenta accreta 252
pathophysiology of 98	hospital systems for care of 341–7	for deep vein thrombosis after
peripartum hysterectomy and 463	in elective cesarean for adherent	placenta accreta surgery 270
placenta accreta risk and 248	placenta 10	internal iliac artery ligation for 442
*	*	, 0

misoprostol use after prophylactic	changes in 157	severe acute maternal morbidity in
oxytocin 301	classic factors of recent findings	504
non-pneumatic anti-shock garment use in 559	157 for secondary PPH 467	septic transfusion reaction 37 severe acute maternal morbidity 147–51,
thromboprophylaxis in placenta	for severe acute maternal morbidity	499–511
accreta 256	505	attributed to hemorrhage 505
use of ergot alkaloids in third stage of	for tamponade test 392	cf near miss 499
labor 104	for uterine atony 356 identification of by midwife 549	definition 499 identification of 501
prostaglandin, excessive bleeding at cesarean section	importance in out-of-hospital	incidence 501
and 449	deliveries 571	increasing incidence 506
for uterine atony 358	increased PPH incidence and 152	main causes 504
injectable 104 isolation of 355	primary prevention and severe acute	measures to reduce 508–11 mortality and 501
see also misoprostol	maternal morbidity 508 Royal College of Obstetricians and	outcomes after 508
use in third stage of labor 96, 104	Gynaecologists (RCOG),	risk factors for 505
pseudoaneurysm 218	guidelines for use of intrauterine	sexual intercourse avoidance in placenta
angiographic proof 222, 223, 471 causes 222	balloon 385	accreta 251
of uterine artery 13	management recommendations 551 standards for prevention and	Sheehan syndrome 533 shivering and misoprostol 289
pulmonary edema 409	treatment of PPH 166	shock,
pulmonary embolism 356	rupture, see uterine rupture	cardiovascular physiology of 332
pyrexia,	rural deliveries, blood loss assessment in	decreased recovery times with
misoprostol administration route and 299	86 Rüsch hydrostatic urological balloon	non-pneumatic anti-shock garment 323
misoprostol and 289	378	identification of 550
PPH incidence and 156	experience in Italy 382	in acute uterine inversion 185
		in placental abruption 230
quality Dannlan modile 01 02	S1 sagment 6	internal iliac artery ligation for 444
quality Doppler profile 91, 92	S1 segment 6 abnormal placentation in 22	stages of 74 shock index 335
	placental invasion 267	side-effects,
re-laparotomy 15	uterovaginal blood supply 19–23	of blood transfusions 587
recombinant activated factor VII 359,	S2 segment 6	of carbetocin 364, 366
415–28 recommendations,	abnormal placentation in 22 placental invasion 267	of carboprost 357 of ergometrine 115, 357
for non-pneumatic anti-shock	segment of uterovaginal blood	of misoprostol 115, 276, 278, 289,
garment 318	supply 19–23	299, 358
for use of recombinant activated	safety,	of oxytocin 299, 356
factor VII 427–8	of cell salvage methods in obstetrics	oxytocin lack of 115
global for active management of third stage of labor 120–4	578 of fibrin sealants 475	safety of fibrin sealants 475 skills teaching 308–9
of Confidential Enquiry into	of recombinant activated factor VII	sample scenario for PPH due to
Maternal and Child Health	419, 427	uterine atony 312
166	scenario teaching 309–10	sample scenario for PPH not due to
recovery area, PPH in 7 rectum, injuries and ventouse delivery 5	Schultze method 95 sciatica 410	uterine atony 313 stations in training 349
red blood cells,	Scotland,	training and reduction of severe
dose 32	maternal morbidity 136	acute maternal morbidity
for transfusion 30–2	severe acute maternal morbidity in	510
refusal of care 165	501, 507	smoking and risk of placenta previa 231
replenishing lost volume 77 respiratory distress syndrome and early	screening, effect on placenta accreta	South Africa, severe acute maternal morbidity in
cord clamping 105	management in a UK	501, 501
resuscitation,	hospital 247–56	South America, B-Lynch suture
after secondary PPH 468	for morbidly adherent placentas 250	compression suture use in 438
hemostatic 25 non-pneumatic anti-shock garment	for placenta accreta 250 prenatal screening for placenta	statistics, first national register of 64
and 321	accreta 240–1	for PPH incidence and risk factors
retained placenta 494	sealants 474–6	133–43
PPH incidence and 156	secondary autoimmune	how to measure PPH 65
prevalence 138	thrombocytopenia 201	stepwise devascularization 439–40, 452
retained products of conception 494 retractors, for obstetric hemorrhage	secondary PPH 466–71 causes 467	in major PPH 20 subinvolution 494
equipment tray 314–5	management 468	secondary PPH after 466
retroperitoneal hematoma 14	resuscitation 468	substandard care 3
risk factors,	risk factors for 467	substandard management,
for bleeding from lower genital tract 194	Sengstaken–Blakemore tube 378, 381	of placenta previa 163 of placental abruption 162
for placenta accreta 240, 248, 263	sepsis, after tamponade 383	of PPH 163
for placenta previa 231	as a cause of consumptive	sulprostone use in placenta accreta
for placental abruption 227, 228	coagulopathy 205	management 244
for PPH 139-43, 539	peripartum hysterectomy and 463	supralevator hematoma 197

surgery,	lessons from aviation 562	MamaNatalie® birthing simulator
as a risk factor for placenta previa	simulations for training of 564	602-3
and accreta 98	teratogenicity, of misoprostol 276, 284	mandatory state-wide in Illinois
conservative management 433-40	termination of pregnancy using	348
costs of 541	misoprostol 285	methods used 564
for abdominal pregnancy 585	The Netherlands,	modern teaching/learning modalitie
for internal iliac artery ligation	planned home deliveries in 572	for PPH management
443–4	severe acute maternal morbidity in	514–18
intraoperative autologous blood	501	of midwives 552
transfusions 577–82	third stage of labor,	simulations 349, 516, 564
position of surgeon for internal iliac	active management 101–6	skills stations 349
artery ligation 446	definition 113	tranexamic acid 4, 36
postsurgical packing 458	management options for midwife	use in PPH 358
use in Jehovah's Witnesses 590	550	use in secondary PPH 471
use in low resource settings 541	use of misoprostol in 279	transfusion,
suture diagrams 315, 316	third stage of labor,	ABO compatibility 31
Sweden, development of national registry	pathophysiology of PPH and 94–9	after massive resuscitation 27
of vital statistics 64	role of oxytocin in 95	autologous 577–82
swiss-cheese placenta 241	role of prostaglandins in 96	use in Jehovah's Witnesses 590
Syntocinon, see oxytocin	three-dimensional color power Doppler	blood component administration 33
Syntometrine 103, 114	ultrasound for placenta accreta	blood transfusion refusal care
cf carbetocin 363	249	pathway 595
use in secondary PPH 469	three-dimensional ultrasound, for placenta	care plan for women in labor
warning on use 66	accreta 249	refusing blood transfusion
systemic lupus erythematosus 201	thrombin, prevalence of disorders 139	597
systolic blood pressure, relationship with	thrombin generation patterns 45	cell salvage methods 578
intraluminal pressure 374	thrombocytopenia 199	checklist for women in labor
intratumnal pressure 374	drug-induced 202	refusing blood transfusion
	gestational 200	599
tamponade,	heparin-induced 202	complications of 37–41
algorithm for use of internal uterine	HIV-associated 202	delay and litigation 530
balloon 385	incidental 200	hypotension after cell salvage 581
Belfort–Dildy Obstetrical	secondary autoimmune 201	
		infection after and litigation 529
Tamponade System 460 care after successful 379	topical hemostatic agents for 485	intraoperative autologous blood transfusions 577–82
	with microangiopathy 202–4 thromboelastography 49	intravenous fluids for volume
cf hysterectomy 383	thromboelastometry 49	
experience in Italy 381–5 FIGO guidelines on 615	thromboembolism after embolization	expansion 78 Jehovah's Witnesses and 587–92
general principles 377	410	large volume transfusion protocol
internal uterine 377–80	thrombogenic bileaflet valves 207	349, 350
materials for obstetric hemorrhage	thromboprophylaxis in placenta accreta	management of obstetric
equipment tray 315	256	hemorrhage 30–41
pelvic pressure pack 458–60	thrombotic thrombocytopenic purpura	massive transfusion,
principle of action 381	203	complications 27
test volume 372	TISSEEL TM 475, 481–5	protocols 26
using Rüsch hydrostatic urological	tocolytics and masked abruption 191	new approaches 48–51
balloon in Italy 382–5	topical hemostatic agents 480–5	products for 30–4
uterine-specific cf non-specific	bowel obstruction 484	refusal care pathway 595
balloons 387	development 480	refusal of blood products by womer
tamponade algorithm for 390	indications for 480	165
	see also fibrin sealants	
tamponade test 369–75, 377, 381, 388		use during placenta accreta surgery 268
complications 394	tourniquets, isthmial 451	
patient positioning for 393		use in Japan 171
postinsertion observation 395	triple 451 traditional birth attendants,	wrong blood and litigation 528
prevention of balloon displacement 394		transfusion-related acute lung injury 27,
	blood loss assessment by 86	39, 587
removal of balloon and follow-up 396	interventions used by 60	transfusion-related circulatory overload
risk factors indication of use and	misoprostol efficacy at community level 353	27, 40
insertion 392		transfusion-related graft-versus-host disease 27
	role in community-based continuum	transfusion-related immunomodulation
stages of use 392–6	of care use 556	
Tanzania, MamaNatalie® newborn simulator	use of kangas in Tanzania to measure	27, 587
	blood loss 83, 353, 557	transportation,
trials 602	use of misoprostol by 284	barriers to 559
misoprostol efficacy at community	training,	delays and non-pneumatic
level in 353	cost-effectiveness 565	anti-shock garment use 32!
severe acute maternal morbidity in	courses and workshops 518	in low resource settings 543
501	drills 564	non-pneumatic anti-shock garment
use of kanga to measure blood loss	for teamwork 562–6	and 315, 318
83, 353, 557	hands-on 516	problems and maternal morbidity
teamwork,	knitted uterus for teaching purposes	and mortality 308
cost-effectiveness 565	517	reduction of severe acute maternal
in emergency care 562	lecture-based 516	morbidity and 510

trials for non-pneumatic anti-shock	severe acute maternal morbidity in	diagrammatic representation at rest
garment use during 327	501, 507	and at term 94
trauma 185–91 anti-shock garments for 318–20	topical hemostatic agent use in 484 uterine activity and placental separation	endocrine mechanisms of control 95 mechanical events at delivery 94
blunt abdominal trauma 189–91	94	uterine packing 379
prevalence 138	uterine anastomotic system 267	uterine rupture 14, 164, 188–9
trial of labor 189	uterine arteries,	after blunt abdominal trauma 191
triple tourniquet technique 451	anastomosis with vaginal arteries 20	incidence 189
trophoblast invasion, patterns of 56	bilateral embolization 470 blood flow, at term 181	obstructed labor and 188 peripartum hysterectomy and 463
placenta previa and 98	branching patterns 399	previous cesarean section and 188
PPH and 58	diameter increase during pregnancy	severe acute maternal morbidity after
pre-eclampsia and 57	181	507
trophoblastic disease 495	effect of balloon tamponade on 375 embolization in placenta accreta	uterine scarring as a risk factor for placenta previa and accreta 98
	management 244	uterine trauma and peripartum
UK,	fetal nourishment and 180	hysterectomy 463
accurate PPH rate determination 153	ligation 452	uterine vascular malformations 218–24 utero-ovarian communicating arteries,
algorithm for PPH management 167	multigate spectral Doppler analysis 90	prepregnancy hemodynamics
maternal mortality 135	prepregnancy hemodynamics 177	179
from PPH in 162–7	pseudoaneurysm 13	uteroplacental vasculature 489
placenta accreta management in	segmental concept of anatomy 19	uterotonic agents 101–5
247–56 severe acute maternal morbidity in	uterine atony, after elective cesarean section 8	uterotonic therapies 359 uterotonics,
England and Scotland 501	approaches to 381	administration and choices of 114
unplanned home deliveries in 572	Bakri balloon for 387	cf tamponade 388
use of cell salvage methods in 579–80	carbetocin for 361	choice of 4
ultrasound,	carboprost for 357 cf vaginal trauma 5	community-based continuum of care use 556
abdominal pregnancy diagnosis 584	community-level management 353	cost of 115
Bakri balloon 375	embolization and balloon catheter	ergot alkaloids 355
before embolization 406	placement 398	EUPHRATES consensus on 110
diagnosis of placenta previa by 232 Doppler imaging,	ergometrine for 357 identification 355	FIGO guidelines on 609 first-line 372, 388
for placenta accreta 248, 249	in vaginal delivery PPH 4	in placenta accreta management 255
for vascular malformations 219, 220,	intraluminal pressure readings in 369	recommendations for administration
221 placenta accreta diagnosis 247, 248	medical therapies 355 medical therapy for 355–359	361 use in secondary PPH 469
prenatal screening for 240–1	misoprostol cf oxytocin for 296	uterovaginal balloon system 458–60
portable machine 91	misoprostol for 357	uterovaginal blood supply 19–23
three-dimensional,	oxytocin for 356–7	uterus,
color power Doppler for placenta accreta 249	pathophysiology of 97 peripartum hysterectomy and 463	abnormal vasculature and secondary PPH 467
for placenta accreta 249	postpartum pathology 495	acute inversion of 185–8
vascular supply of pelvis 399-400	prevalence 138	arteriovenous malformations of 495
umbilical cord,	prostaglandins for 358	bimanual compression of 434
clamping recommendations 115 delayed clamping 118	recombinant factor VII 415 risk factors for 356	bleeding from during cesarean section 448
early clamping of 105	S1 bleeding and 6	bleeding from uterine incision at
FIGO guidelines on management	sample scenarios for training 312,	cesarean section 449
611	313	chronic inversion of 188
see also controlled cord traction unlawful practice of medicine 527	secondary PPH after 466 surgical steps to arrest 451	collateral arteries 179 evacuation for secondary PPH 469
ureter,	tamponade for 377, 381	extrinsic arteries 178
damage during internal iliac artery	underlying causes 58	FIGO guidelines on bimanual
ligation 446	uterine blood flow,	compression 613
injury to 5 stenting of in placenta accreta 254	hemodynamic changes in 89–93 quality Doppler profile 91, 92	hemodynamic changes during pregnancy 177–83
US Agency for International	uterine embolization, anatomic reasons	intrinsic arteries 179
Development, POPPHI 121–3	for failure 20	knitted model for teaching purposes
USA,	uterine inversion,	517
accurate PPH rate determination 154	hydrostatic repositioning 16 manual repositioning 15	lower segment, postpartum pathology of 491–3
B-Lynch suture compression suture	PPH in 15	parallel blood flow circuits in 181
use in 438	uterine massage 116, 119	postpartum 489–97
development of hospital systems for PPH in New York 342–7	FIGO guidelines on 610	resection after placenta accreta
Illinois model of training 348–50	instruction of mother in self-massage 119	surgery 269 stepwise devascularization of 439–40
maternal morbidity 137	uterine muscle,	stretching of cavity by Bakri balloon
maternal mortality 136	contraction and control of bleeding	375
planned home deliveries in 572	95	subinvolution 494

in secondary PPH 467, 471 vascular malformations, wall structure and compliance with tamponade 374 clinical presentation 219 diagnosis 219 management 220 warfarin 207 PPH and 218-24 vagina, WHO, bleeding from lower genital tract prevention of 222 guidance on management of third 193-8 types 218 stage of labor 121 examination for trauma 4, 5 vasopressors 522 modern teaching/learning modalities vaginal arteries, anastomoses with uterine venous thromboembolism, anticoagulant for PPH management 514 arteries 20 recommendations 118 therapy during pregnancy and vaginal delivery, peripartum 206-8 terminology for near misses 147 carbetocin use at 363 ventilation, terminology for severe acute European consensus on prevention invasive 521 maternal morbidity 504 and management of PPH at non-invasive 521 World Maternal Antifibrinolytic Trial 110 ventouse delivery, 359 hysterotomy for compression suture incorrect cup placement 6 wound dehiscence and secondary PPH after 436 PPH scenario 5 467 PPH incidence 156 related lacerations 5 PPH scenario 4 vesicouterine system (neovascularization) vaginal hematoma, topical hemostatic 266 Zambia, agents for 485 visual assessment of PPH 71, 82 blood loss assessment by chittengue vaginal trauma, visual estimation of blood loss 71, 134 354 after ventouse delivery 5 vitamin K metabolism deficiency 214 non-pneumatic anti-shock garment as cause of PPH 4 volume deficit classification 130 trials in 327, 332 prevalence 138 volume overload 40 Zanzibar, MamaNatalie® newborn repair 195 volume resuscitation 45 simulator trials 603 secondary PPH after 466 von Willebrand disease 96, 208-10 Zimbabwe, non-pneumatic anti-shock and PPH risk 140 variant Creutzfeldt-Jakob disease 587 garment trials in 327, 332